Note: Descriptions are shown in the official language in which they were submitted.
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
METHODS OF TREATMENT USING A JAK INHIBITOR COMPOUND
BACKGROUND OF THE INVENTION
Field of the invention
The present invention is directed to methods for treating ocular and certain
respiratory
diseases using a particular JAK inhibitor compound or a pharmaceutically-
acceptable salt
thereof.
State of the Art
Cytokines are intercellular signaling molecules which include chemokines,
interferons, interleukins, lymphokines, and tumour necrosis factor. Cytokines
are critical for
normal cell growth and immunoregulation but also drive immune-mediated
diseases and
contribute to the growth of malignant cells. Elevated levels of many cytokines
have been
implicated in the pathology of a large number of diseases or conditions,
particularly those
diseases characterized by inflammation. Many of the cytokines implicated in
disease act
through signaling pathways dependent upon the Janus family of tyrosine kinases
(JAKs),
which signal through the Signal Transducer and Activator of Transcription
(STAT) family of
transcription factors.
The JAK family comprises four members, JAK1, JAK2, JAK3, and tyrosine kinase 2
(TYK2). Binding of cytokine to a JAK-dependent cytokine receptor induces
receptor
dimerization which results in phosphorylation of tyrosine residues on the JAK
kinase,
effecting JAK activation. Phosphorylated JAKs, in turn, bind and phosphorylate
various
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
STAT proteins which dimerize, internalize in the cell nucleus and directly
modulate gene
transcription, leading, among other effects, to the downstream effects
associated with
inflammatory disease. The JAKs usually associate with cytokine receptors in
pairs as
homodimers or heterodimers. Specific cytokines are associated with specific
JAK pairings.
Each of the four members of the JAK family is implicated in the signaling of
at least one of
the cytokines associated with inflammation.
Inflammation plays a prominent role in many ocular diseases, including
uveitis,
diabetic retinopathy, diabetic macular edema, dry eye disease, age-related
macular
degeneration, and atopic keratoconjunctivitis. Uveitis encompasses multiple
intraocular
inflammatory conditions and is often autoimmune, arising without a known
infectious
trigger. The condition is estimated to affect about 2 million patients in the
US. In some
patients, the chronic inflammation associated with uveitis leads to tissue
destruction, and it is
the fifth leading cause of blindness in the US. Cytokines elevated in uveitis
patients' eyes that
signal through the JAK-STAT pathway include IL-2, IL-4, IL-5, IL-6, IL-10, IL-
23, and
IFN-y. (Horai and Caspi, J Interferon Clpiokine Res, 2011, 31, 733-744; Ooi et
al, Clinical
Medicine and Research, 2006, 4, 294-309). Existing therapies for uveitis are
often
suboptimal, and many patients are poorly controlled. Steroids, while often
effective, are
associated with cataracts and increased intraocular pressure/glaucoma.
Diabetic retinopathy (DR) is caused by damage to the blood vessels in the
retina. It is
the most common cause of vision loss among people with diabetes. Angiogenic as
well as
inflammatory pathways play an important role in the disease. Often, DR will
progress to
diabetic macular edema (DME), the most frequent cause of visual loss in
patients with
diabetes. The condition is estimated to affect about 1.5 million patients in
the US alone, of
whom about 20 % have disease affecting both eyes. Cytokines which signal
through the
JAK-STAT pathway, such as IL-6, as well as other cytokines, such as IP-10 and
MCP-1
(alternatively termed CCL2), whose production is driven in part by JAK-STAT
pathway
signaling, are believed to play a role in the inflammation associated with
DR/DME
(Abcouwer, J Clin Cell Immunol, 2013, Suppl I, 1-12; Sohn et al., American
Journal of
Opthalmology, 2011, 152, 686-694; Owen and Hartnett, Curr Diab Rep, 2013, 13,
476-480;
Cheung et al, Molecular Vision, 2012, 18, 830-837; Dong et al, Molecular
Vision, 2013, 19,
1734-1746; Funatsu et al, Ophthalmology, 2009, 116, 73-79). The existing
therapies for
2
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
DME are suboptimal: intravitreal anti-VEGF treatments are only effective in a
fraction of
patients and steroids are associated with cataracts and increased intraocular
pressure.
Dry eye disease (DED) is a multifactorial disorder that affects approximately
5
million patients in the US. Ocular surface inflammation is believed to play an
important role
in the development and propagation of this disease. Elevated levels of
cytokines such as IL-1,
IL-2, IL-4, IL-5, IL-6, and IFN-y have been noted in the ocular fluids of
patients with DED.
(Stevenson et al, Arch Ophthalmol, 2012, 130, 90-100), and the levels often
correlated with
disease severity. Age-related macular degeneration and atopic
keratoconjunctivitis are also
thought to be associated with JAK-dependent cytokines.
Given the number of cytokines elevated in inflammatory diseases and that each
cytokine is associated with a particular JAK pairing, it would be desirable to
provide a
chemical inhibitor with pan-activity against all members of the JAK family for
the treatment
of ocular disease. However, the broad anti-inflammatory effect of such
inhibitors could
suppress normal immune cell function, potentially leading to increased risk of
infection. It
would be desirable, therefore, to provide an inhibitor that can be locally
delivered to the site
of action in the eye, thereby limiting the potential for adverse systemic
immunosuppression.
Commonly assigned U.S. Application Serial No. 15/341,226, filed November 02,
2016 discloses diamino compounds useful as JAK inhibitors. In particular, the
compound
5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-
imidazo[4,5-
c]pyridin-2-y1)-1H-indazol-6-yl)phenol (compound 1)
HO
HN-N
1
is specifically disclosed in the application as a potent pan-JAK inhibitor.
This application
discloses various uses of compound 1, in particular treatment of respiratory
diseases
including asthma, chronic obstructive pulmonary disease, cystic fibrosis,
pneumonitis,
interstitial lung diseases (including idiopathic pulmonary fibrosis), acute
lung injury, acute
3
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
respiratory distress syndrome, bronchitis, emphysema and bronchiolitis
obliterans. However,
this application does not disclose the use of compound 1 for the treatment of
ocular disease.
SUMMARY OF THE INVENTION
The present invention relates to methods of treating ocular diseases or
symptoms
thereof using the JAK inhibitor 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-
y1)-4,5,6,7-
tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-111-indazol-6-yl)phenol or a
pharmaceutically-
acceptable salt thereof
In one aspect, the invention provides a method of treating an ocular disease
in a
human patient, the method comprising administering to the eye of the patient,
the compound
5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-
imidazo[4,5-
c]pyridin-2-y1)-1H-indazol-6-y1)phenol of formula
HO
NN
HN-N
1
hereinafter compound 1, or a pharmaceutically-acceptable salt thereof.
In one aspect the ocular disease is uveitis, diabetic retinopathy, diabetic
macular
edema, dry eye disease, age-related macular degeneration, or atopic
keratoconjunctivitis. In
particular, the ocular disease is uveitis or diabetic macular edema.
In another aspect, the invention provides a pharmaceutical composition of 5-
ethyl-2-
fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-imidazo[4,5-
c]pyridin-2-y1)-
1H-indazol-6-yl)phenol (compound 1) or a pharmaceutically-acceptable salt
thereof, wherein
the pharmaceutical composition is suitable for administration directly to the
eye of a patient.
The present invention further relates to methods of using compound 1 to treat
certain
specific respiratory diseases.
In one aspect, the invention provides a method of treating a respiratory
disease in a
mammal, the method comprising administering to the mammal a pharmaceutical
composition
comprising compound 1 or a pharmaceutically acceptable salt thereof, and a
4
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
pharmaceutically-acceptable carrier, wherein the respiratory disease is a lung
infection, a
helminthic infection, pulmonary arterial hypertension, sarcoidosis,
lymphangioleiomyomatosis, bronchiectasis, or an infiltrative pulmonary
disease.
In yet another aspect, the invention provides a method of treating a
respiratory disease
in a mammal, the method comprising administering to the mammal a
pharmaceutical
composition comprising compound 1 or a pharmaceutically acceptable salt
thereof, and a
pharmaceutically-acceptable carrier, wherein the respiratory disease is drug-
induced
pneumonitis, fungal induced pneumonitis, allergic bronchopulmonary
aspergillosis,
hypersensitivity pneumonitis, eosinophilic granulomatosis with polyangiitis,
idiopathic acute
eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia,
hypereosinophilic
syndrome, Ltiffler syndrome, bronchiolitis obliterans organizing pneumonia, or
immune-
checkpoint-inhibitor induced pneumonitis.
DETAILED DESCRIPTION OF THE INVENTION
Chemical structures are named herein according to TUPAC conventions as
implemented in ChemDraw software (PerkinElmer, Inc., Cambridge, MA).
Furthermore, the imidazo portion of the tetrahydroimidazopyridine moiety in
the
structure of the present compound exists in tautomeric forms. The compound
could
equivalently be represented as
HO
N
HN-
According to the IUPAC convention, these representations give rise to
different numbering
of the atoms of the imiclazopyridine portion. Accordingly this structure is
designated 5-ethyl-
2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrah ydro-3H-i m idazo[4,5-
c]pyri di n-2-y1)-
1H-inclazol-6-y1)phenol. It will be understood that although structures are
shown, or named,
in a particular form, the invention also includes the tautomer thereof.
5
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Definitions
When describing the present invention, the following terms have the following
meanings unless otherwise indicated.
The singular terms "a," "an" and "the" include the corresponding plural terms
unless
the context of use clearly dictates otherwise.
The term "about" means 5 percent of the specified value.
The term "therapeutically effective amount" means an amount sufficient to
effect
treatment when administered to a patient in need of treatment, e.g., the
amount needed to
obtain the desired therapeutic effect.
The term "treating" or "treatment" means preventing, ameliorating or
suppressing the
medical condition, disease or disorder being treated (e.g., a respiratory
disease) in a patient
(particularly a human); or alleviating the symptoms of the medical condition,
disease or
disorder.
The term "unit dosage form" or "unit doses" means a physically discrete unit
suitable
for dosing a patient, i.e., each unit containing a predetermined quantity of a
therapeutic agent
calculated to produce a therapeutic effect either alone or in combination with
one or more
additional units. Examples include capsules, tablets and the like.
All other terms used herein are intended to have their ordinary meaning as
understood
by persons having ordinary skill in the art to which they pertain.
The term "pharmaceutically-acceptable" means acceptable for administration to
a
patient (e.g., having acceptable safety for the specified usage).
The term "pharmaceutically-acceptable salt" means a salt prepared from an acid
and a
base (including zwitterions) that is acceptable for administration to a
patient (e.g., a salt
having acceptable safety for a given dosage regime).
Representative pharmaceutically acceptable salts include salts of acetic,
ascorbic,
benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, edisylic,
fumaric, gentisic,
gluconic, glucoronic, glutamic, hippuric, hydrobromic, hydrochloric,
isethionic, lactic,
lactobionic, maleic, malic, mandelic, methanesulfonic, mucic,
naphthalenesulfonic,
naphthalene-1,5-disulfonic, naphthalene-2,6-disulfonic, nicotinic, nitric,
orotic, oxalic,
pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-
toluenesulfonic and xinafoic
acid, and the like.
6
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
The term "salt thereof' means a compound formed when the hydrogen of an acid
is
replaced by a cation, such as a metal cation or an organic cation and the
like.
Compound 1
The present method invention employs 5-ethy1-2-fluoro-4-(3-(5-(1-
methylpiperidin-
4-y1)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol
(compound 1)
HO
NN
FiN-N
1
or a pharmaceutically-acceptable salt thereof.
Compound 1 may be prepared as described in U.S. Application Serial No.
15/341,226
or in the appended examples.
In one aspect of the invention, compound 1 is employed in the form of a
crystalline
freebase hydrate characterized by a powder X-ray diffraction (PXRD) pattern
having
significant diffraction peaks, among other peaks, at 20 values of 6.20 0.20,
9.58 0.20,
17.53 0.20, 19.28 0.20, and 21.51 0.20. The preparation of the crystalline
hydrate is also
described in U.S. Serial No. 15/341,226 and in the examples below.
Pharmaceutical Compositions
The present compound, 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-
4,5,6,7-
tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-y1)phenol (1) and
pharmaceutically-
acceptable salts thereof is typically used in the form of a pharmaceutical
composition or
formulation. Such pharmaceutical compositions may advantageously be
administered to a
patient by any acceptable route of administration including, but not limited
to, oral,
inhalation, optical injection, topical (including transdermal), rectal, nasal,
and parenteral
modes of administration.
The pharmaceutical compositions utilized in the invention typically contain a
therapeutically effective amount of compound 1. Those skilled in the art will
recognize,
however, that a pharmaceutical composition may contain more than a
therapeutically
7
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
effective amount, i.e., bulk compositions, or less than a therapeutically
effective amount, i.e.,
individual unit doses designed for multiple administration to achieve a
therapeutically
effective amount. When discussing compositions and uses, compound I may also
be referred
to herein as 'active agent'.
Typically, pharmaceutical compositions will contain from about 0.01 to about
95%
by weight of the active agent; including, for example, from about 0.05 to
about 30% by
weight; and from about 0.1 % to about 10% by weight of the active agent.
Any conventional carrier or excipient may be used in the pharmaceutical
compositions utilized in the invention. The choice of a particular carrier or
excipient, or
combinations of carriers or excipients, will depend on the mode of
administration being used
to treat a particular patient or type of medical condition or disease state.
In this regard, the
preparation of a suitable pharmaceutical composition for a particular mode of
administration
is well within the scope of those skilled in the pharmaceutical arts.
Additionally, the carriers
or excipients used in the pharmaceutical compositions of this invention are
commercially-
available. By way of further illustration, conventional formulation techniques
are described
in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott
Williams &
White, Baltimore, Maryland (2000); and H.C. Ansel et al., Pharmaceutical
Dosage Forms
and Drug Delivery Systems, 7th Edition, Lippincott Williams & White,
Baltimore, Maryland
(1999).
Representative examples of materials which can serve as pharmaceutically
acceptable
carriers include, but are not limited to, the following: sugars, such as
lactose, glucose and
sucrose; starches, such as corn starch and potato starch; cellulose, such as
microcrystalline
cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl
cellulose and
cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such
as cocoa butter
and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower
oil, sesame oil,
olive oil, corn oil and soybean oil; glycols, such as propylene glycol;
polyols, such as
glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl
oleate and ethyl
laurate; agar; buffering agents, such as magnesium hydroxide and aluminum
hydroxide;
alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol; phosphate
buffer solutions; and other non-toxic compatible substances employed in
pharmaceutical
compositions.
8
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Pharmaceutical compositions are typically prepared by thoroughly and
intimately
mixing or blending the active agent with a pharmaceutically-acceptable carrier
and one or
more optional ingredients. The resulting uniformly blended mixture can then be
shaped or
loaded into tablets, capsules, pills and the like using conventional
procedures and equipment.
In one aspect, the pharmaceutical composition is suitable for ocular
injection. In this
aspect, the compound may be formulated as a sterile aqueous suspension or
solution. Useful
excipients that may be included in such an aqueous formulation include
polysorbate 80,
carboxymethylcellulose, potassium chloride, calcium chloride, magnesium
chloride, sodium
acetate, sodium citrate, histidine, a-a-trehalose dihydrate, sucrose,
polysorbate 20,
hydroxypropyl-fl-cyclodextrin, and sodium phosphate. Benzyl alcohol may serve
as a
preservative and sodium chloride may be included to adjust tonicity. In
addition,
hydrochloric acid and/or sodium hydroxide may be added to the solution for pH
adjustment
Aqueous formulations for ocular injection may be prepared as preservative-
free.
In another aspect, the pharmaceutical composition is suitable for inhaled
administration. Pharmaceutical compositions for inhaled administration are
typically in the
form of an aerosol or a powder. Such compositions are generally administered
using inhaler
delivery devices, such as a dry powder inhaler (DPI), a metered-dose inhaler
(MDI), a
nebulizer inhaler, or a similar delivery device.
In a particular embodiment, the pharmaceutical composition is administered by
inhalation using a dry powder inhaler. Such dry powder inhalers typically
administer the
pharmaceutical composition as a free-flowing powder that is dispersed in a
patient's air-
stream during inspiration. In order to achieve a free-flowing powder
composition, the
therapeutic agent is typically formulated with a suitable excipient such as
lactose, starch,
mannitol, dextrose, polylactic acid (PLA), polylactide-co-glycolide (PLGA) or
combinations
thereof. Typically, the therapeutic agent is micronized and combined with a
suitable carrier
to form a composition suitable for inhalation.
A representative pharmaceutical composition for use in a dry powder inhaler
comprises lactose and the compound of the invention in micronized form. Such a
dry
powder composition can be made, for example, by combining dry milled lactose
with the
therapeutic agent and then dry blending the components. The composition is
then typically
9
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
loaded into a dry powder dispenser, or into inhalation cartridges or capsules
for use with a
dry powder delivery device.
Dry powder inhaler delivery devices suitable for administering therapeutic
agents by
inhalation are described in the art and examples of such devices are
commercially available.
For example, representative dry powder inhaler delivery devices or products
include Aeolizer
(Novartis); Airmax (WAX); ClickHaler (Innovata Biomed); Diskhaler
(GlaxoSmithKline);
Diskus/Accuhaler (GlaxoSmithKline); Ellipta (GlaxoSmithKline); Easyhaler
(Orion
Pharma); Eclipse (Aventis); FlowCaps (Hovione); Handihaler (Boehringer
Ingelheim);
Pulvinal (Chiesi); Rotahaler (GlaxoSmithKline); SkyeHaler/Certihaler
(SkyePharma);
Twisthaler (Schering-Plough); Turbuhaler (AstraZeneca); Ultrahaler (Aventis);
and the like.
In another particular embodiment, the pharmaceutical composition is
administered by
inhalation using a metered-dose inhaler. Such metered-dose inhalers typically
discharge a
measured amount of a therapeutic agent using a compressed propellant gas.
Accordingly,
pharmaceutical compositions administered using a metered-dose inhaler
typically comprise a
solution or suspension of the therapeutic agent in a liquefied propellant. Any
suitable
liquefied propellant may be employed including hydrofluoroalkanes (HFAs), such
as 1,1,1,2-
tetrafluoroethane (1-WA. 134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane, (HFA
227); and
chlorofluorocarbons, such as CC13F. In a particular embodiment, the propellant
is
hydrofluoroalkanes. In some embodiments, the hydrofluoroalkane formulation
contains a co-
solvent, such as ethanol or pentane, and/or a surfactant, such as sorbitan
trioleate, oleic acid,
lecithin, and glycerin.
A representative pharmaceutical composition for use in a metered-dose inhaler
comprises from about 0.01% to about 5% by weight of the compound of the
invention; from
about 0% to about 20% by weight ethanol; and from about 0% to about 5% by
weight
surfactant; with the remainder being an FIFA propellant. Such compositions are
typically
prepared by adding chilled or pressurized hydrofluoroalkane to a suitable
container
containing the therapeutic agent, ethanol (if present) and the surfactant (if
present). To
prepare a suspension, the therapeutic agent is micronized and then combined
with the
propellant The composition is then loaded into an aerosol canister, which
typically forms a
portion of a metered-dose inhaler device.
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Metered-dose inhaler devices suitable for administering therapeutic agents by
inhalation are described in the art and examples of such devices are
commercially available.
For example, representative metered-dose inhaler devices or products include
AeroBid
Inhaler System (Forest Pharmaceuticals); Atrovent Inhalation Aerosol
(Boehringer
Ingelheim); Flovent (GlaxoSmithKline); Maxair Inhaler (3M); Proventil Inhaler
(Schering);
Serevent Inhalation Aerosol (GlaxoSmithKline); and the like.
In another particular aspect, the pharmaceutical composition is administered
by
inhalation using a nebulizer inhaler. Such nebulizer devices typically produce
a stream of
high velocity air that causes the pharmaceutical composition to spray as a
mist that is carried
into the patient's respiratory tract. Accordingly, when formulated for use in
a nebulizer
inhaler, the therapeutic agent can be dissolved in a suitable carrier to form
a solution.
Alternatively, the therapeutic agent can be micronized or nanomilled and
combined with a
suitable carrier to form a suspension.
A representative pharmaceutical composition for use in a nebulizer inhaler
comprises
a solution or suspension comprising from about 0.05 1.1g/mL to about 20 mg/mL
of the
compound of the invention and excipients compatible with nebulized
formulations. In one
embodiment, the solution has a pH of about 3 to about 8.
Nebulizer devices suitable for administering therapeutic agents by inhalation
are
described in the art and examples of such devices are commercially available.
For example,
representative nebulizer devices or products include the Respimat Softmist
Inhaler
(Boehringer Ingelheim); the AERx Pulmonary Delivery System (Aradigm Corp.);
the PAR!
LC Plus Reusable Nebulizer (Pan i (imbH); and the like.
In yet another aspect, the pharmaceutical compositions of the invention may
alternatively be prepared in a dosage form intended for oral administration.
Suitable
pharmaceutical compositions for oral administration may be in the form of
capsules, tablets,
pills, lozenges, cachets, dragees, powders, granules; or as a solution or a
suspension in an
aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil liquid
emulsion; or as an
elixir or syrup; and the like; each containing a predetermined amount of a
compound of the
present invention as an active ingredient.
When intended for oral administration in a solid dosage form, the
pharmaceutical
compositions of the invention will typically comprise the active agent and one
or more
11
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium
phosphate.
Optionally or alternatively, such solid dosage forms may also comprise:
fillers or extenders,
binders, humectants, solution retarding agents, absorption accelerators,
wetting agents,
absorbents, lubricants, coloring agents, and buffering agents. Release agents,
wetting agents,
coating agents, sweetening, flavoring and perfuming agents, preservatives and
antioxidants
can also be present in the pharmaceutical compositions of the invention.
Alternative formulations may also include controlled release formulations,
liquid
dosage forms for oral administration, transdermal patches, and parenteral
formulations.
Conventional excipients and methods of preparation of such alternative
formulations are
described, for example, in the reference by Remington, supra.
The following non-limiting examples illustrate representative pharmaceutical
compositions of the present invention.
Aqueous formulation for ocular injection
Each mL of a sterile aqueous suspension includes from 5 mg to 50 mg of
compound
1, sodium chloride for tonicity, 0.99 % (w/v) benzyl alcohol as a
preservative, 0.75 %
carboxymethylcellulose sodium, and 0.04 % polysorbate. Sodium hydroxide or
hydrochloric
acid may be included to adjust pH to 5 to 7.5.
Aqueous formulation for ocular injection
A sterile preservative-free aqueous suspension includes from 5 mg/mL to 50
mg/mL
of compound 1 in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03 %
polysorbate
20, and 5 % sucrose.
Thy Powder Composition
Micronized compound 1 (1 g) is blended with milled lactose (25 g). This
blended
mixture is then loaded into individual blisters of a peelable blister pack in
an amount
sufficient to provide between about 0.1 mg to about 4 mg of the compound of
formula I per
dose. The contents of the blisters are administered using a dry powder
inhaler.
Dty Powder composition
Micronized compound 1 (1 g) is blended with milled lactose (20 g) to form a
bulk
composition having a weight ratio of compound to milled lactose of 1:20. The
blended
composition is packed into a dry powder inhalation device capable of
delivering between
about 0.1 mg to about 4 mg of the compound of formula I per dose.
12
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Metered-Dose Inhaler Composition
Micronized compound 1 (10 g) is dispersed in a solution prepared by dissolving
lecithin (0.2 g) in demineralized water (200 mL). The resulting suspension is
spray dried and
then micronized to form a micronized composition comprising particles having a
mean
diameter less than about 1.5 gm. The micronized composition is then loaded
into metered-
dose inhaler cartridges containing pressurized 1,1,1,2-tetrafluoroethane in an
amount
sufficient to provide about 0.1 mg to about 4 mg of the compound of formula I
per dose
when administered by the metered dose inhaler.
Nebulizer Composition
Compound 1(25 mg) is dissolved in a solution containing 1.5-2.5 equivalents of
hydrochloric acid, followed by addition of sodium hydroxide to adjust the pH
to 3.5 to 5.5
and 3% by weight of glycerol. The solution is stirred well until all the
components are
dissolved. The solution is administered using a nebulizer device that provides
about 0.1 mg
to about 4 mg of the compound of formula I per dose.
Utility
The present compound, 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-
4,5,6,7-
tetrahydro-1H-imiclazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol, (compound
1), has been
shown to be a potent inhibitor of the JAK family of enzymes: JAK1, JAK2, JAK3,
and
TYK2.
Ocular Diseases
Many ocular diseases have been shown to be associated with elevations of
proinflammatory cytokines that rely on the JAK-STAT pathway. Since the
compound of the
invention exhibits potent inhibition at all four JAK enzymes, it is expected
to potently inhibit
the signaling and pathogenic effects of numerous cytokines (such as IL-6, IL-2
and IFNI?),
that signal through JAK, as well as to prevent the increase in other cytokines
(such as MCP-1
and EP-10), whose production is driven by JAK-STAT pathway signaling.
hi particular, the present compound exhibited pIC50 values of 6.7 or greater
(IC50
values of 200 nM or less) for inhibition of 1L-2,
IL-6, and IFNT signaling in the cellular
assays described in Assays 3 to 7, including assays registering inhibition of
the downstream
effects of cytokine elevation.
13
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
The pharmacokinetic study of Assay 8 demonstrated sustained exposure in rabbit
eyes after a single intravitreal injection and a concentration in plasma at
least three orders of
magnitude lower than that observed in vitreous tissue.
Furthermore, intravitreal dosing of the compound of the invention has
demonstrated
significant inhibition of IL-6 induced pSTAT3 in the rat retinaichoroid tissue
as well as
significant inhibition of IFNI induced IP-10 in the rabbit vitreous as well as
retina/choroid
tissues.
It is expected that sustained ocular JAK inhibition in the absence of
significant
systemic levels will result in potent, local anti-inflammatory activity in the
eye without
systemically-driven adverse effects. The compound of the invention is expected
to be
beneficial in a number of ocular diseases that include, but are not limited
to, uveitis, diabetic
retinopathy, diabetic macular edema, dry eye disease, age-related macular
degeneration, and
atopic keratoconjunctivitis.
In particular, uveitis (Horai and Caspi, Jlnterferon Cytokine Res, 2011, 31,
733-744),
diabetic retinopathy (Abcouwer, .1 Clin Cell Immunol, 2013, Suppl 1,1-12),
diabetic macular
edema (Sohn et al., American Journal of Opthamology, 2011, 152, 686-694), dry
eye disease
(Stevenson et al, Arch Ophihalmol, 2012, 130, 90-100), and age-related macular
degeneration (Knickelbein et al, Int Ophthalmol (!in, 2015, 55(3), 63-78) are
characterized
by elevation of certain pro-inflammatory cytokines that signal via the JAK-
STAT pathway.
Accordingly, compounds of the invention may be able to alleviate the
associated ocular
inflammation and reverse disease progression or provide symptom relief.
Retinal vein occlusion (RVO) is a highly prevalent visually disabling disease.
Obstruction of retinal blood flow can lead to damage of the retinal
vasculature, hemorrhage,
and tissue ischemia. Although the causes for RVO are multifactorial, both
vascular as well as
inflammatory mediators have been shown to be important (Deobhakta et al,
International
Journal 61 Inflammation, 2013, article ID 438412). Cytokines which signal
through the JAK-
STAT pathway, such as 1L-6 and 1L-13, as well as other cytokines, such as MCP-
1, whose
production is driven in part by JAK-STAT pathway signaling, have been detected
at elevated
levels in ocular tissues of patients with RVO (Shchuko et al, Indian Journal
of
Ophthalmology, 2015, 63(12), 905-911). Accordingly, compound 1 may be able to
alleviate
the associated ocular inflammation and reverse disease progression or provide
symptom
14
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
relief in this disease. While many patients with RVO are treated by
photocoagulation, this is
an inherently destructive therapy. Anti-VEGF agents are also used, but they
are only
effective in a fraction of patients. Steroid medications that reduce the level
of inflammation
in the eye (Triamcinolone acetonide and dexamethasone implants) have also been
shown to
.. provide beneficial results for patients with certain forms of RVO, but they
have also been
shown to cause cataracts and increased intraocular pressure/glaucoma.
In one aspect, therefore, the invention provides a method of treating an
ocular disease
in a mammal, the method comprising administering 5-ethy1-2-fluoro-4-(3-(5-(1-
methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c] pyridin-2-y1)-1H-
inclazol-6-
.. yl)phenol or a pharmaceutically-acceptable salt thereof to the eye of the
mammal. In one
aspect, the ocular disease is uveitis, diabetic retinopathy, diabetic macular
edema, dry eye
disease, age-related macular degeneration, retinal vein occlusion, or atopic
keratoconjunctivitis. In one aspect, the method comprises administering the
present
compound by intravitreal injection.
Respiratory Diseases
The present compound, 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-
4,5,6,7-
tetrahydro-1H-imiclazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol (1) has
demonstrated
inhibition of T cell activation, inhibition of cytokines associated with
inflammation, and
activity in rodent lung eosinophilia and neutrophilia assays. Therefore, the
compound is
believed to be useful for the treatment of certain specific respiratory
diseases.
Eosinophilic airway inflammation is a characteristic feature of diseases
collectively
termed eosinophilic lung diseases (Cottin et al., Clin. Chest. Med., 2016,
37(3), 535-56).
Eosinophilic diseases have been associated with IL-4, IL-I3 and IL-5
signaling.
Eosinophilic lung diseases include infections (especially helminthic
infections), drug-induced
pneumonitis (induced for example by therapeutic drugs such as antibiotics,
phenytoin,
or 1-tryptophan), fungal-induced pneumonitis (e.g. allergic bronchopulmonary
aspergillosis),
hypersensitivity pneumonitis and eosinophilic granulomatosis with polyangiitis
(formerly
known as Churg-Strauss syndrome). Eosinophilic lung diseases of unknown
etiology include
idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic
pneumonia,
hypereosinophilic syndrome, and Loffler syndrome. Compound 1 has been shown to
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
significantly reduce lung eosinophilia in the rodent airway model of Assay 13
and to potently
inhibit IL-13, IL-4, and 1L-2 signaling in cellular assays.
A polymorphism in the IL-6 gene has been associated with elevated IL-6 levels
and
an increased risk of developing pulmonary arterial hypertension (PAH) (Fang et
al., J Am Soc
Hypertens., Interleukin-6 -572C/G polymorphism is associated with serum
interleukin-6
levels and risk of idiopathic pulmonary arterial hypertension, 2017, ahead of
print).
Corroborating the role of IL-6 in PAH, inhibition of the IL-6 receptor chain
gp130
ameliorated the disease in a rat model of PAH (Huang et al., Can J Cardiol.,
2016, 32(11),
1356.e1-1356.e10). The compound of the invention has been shown to inhibit IL-
6 signaling.
Cytokines such as IFI=Iy, IL-12 and IL-6 have been implicated in a range of
non-
allergic lung diseases such as sarcoidosis, and lymphangioleiomyomatosis (El-
Hashemite et
al., Am. J. Respir. Cell Mol. Biol., 2005, 33, 227-230, and El-Hashemite et
al., Cancer Res.,
2004, 64, 3436-3443 ). The compound of the invention has also been shown to
inhibit IL-6
and IfFNT signaling.
Bronchiectasis and infiltrative pulmonary diseases are diseases associated
with
chronic neutrophilic inflammation. The compound of the invention has been
shown to
inhibit airway neutrophilia in a rodent model.
Pathological T cell activation is critical in the etiology of multiple
respiratory
diseases. Autoreactive T cells play a role in bronchiolitis obliterans
organizing pneumonia
(also termed COP [cryptogenic organizing pneumonia]). More recently, immune-
checkpoint
inhibitor induced pneumonitis, another T cell mediated lung disease emerged
with the
increased use of immune-checkpoint inhibitors. In cancer patients treated with
these T cell
stimulating agents, fatal pneumonitis can develop. The compound of the
invention has been
shown to inhibit activation in T cells isolated from human peripheral blood
mononuclear
cells.
In one aspect, therefore, the invention provides a method of treating a
respiratory
disease in a mammal (e.g., a human), the method comprising administering to
the mammal
5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-
imidazo[4,5-
c]pyridin-2-y1)-1H-indazol-6-yl)phenol or a pharmaceutically acceptable salt
thereof, or a
pharmaceutical composition comprising a pharmaceutically-acceptable carrier
and the
compound of the invention, or a pharmaceutically acceptable salt thereof,
wherein the
16
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
respiratory disease is a lung infection, a helminthic infection, pulmonary
arterial
hypertension, sarcoidosis, lymphangioleiomyomatosis, bronchiectasis, or an
infiltrative
pulmonary disease.
In another aspect, the invention provides a method of treating a respiratory
disease in
a mammal (e.g., a human), the method comprising administering to the mammal
the
compound of the invention, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition comprising a pharmaceutically-acceptable carrier
and the
compound of the invention, or a pharmaceutically acceptable salt thereof,
wherein the
respiratory disease is drug-induced pneumonitis, fungal induced pneumonitis,
allergic
bronchopulmonary aspergillosis, hypersensitivity pneumonitis, eosinophilic
granulomatosis
with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic
eosinophilic
pneumonia, hypereosinophilic syndrome, LOffler syndrome, bronchiolitis
obliterans
organizing pneumonia, or immune-checkpoint-inhibitor induced pneumonitis.
JAK-signaling cytokines also play a major role in the activation of T cells, a
sub-type
of immune cells that is central to many immune processes. Pathological T cell
activation is
critical in the etiology of multiple respiratory diseases. Autoreactive T
cells play a role in
bronchiolitis obliterans organizing pneumonia (also termed COS). Similar to
COS the
etiology of lung transplant rejections is linked to an aberrant T cell
activation of the
recipients T cells by the transplanted donor lung. Lung transplant rejections
may occur early
as Primary Graft Dysfunction (POD), organizing pneumonia (OP), acute rejection
(AR) or
lymphocytic bronchiolitis (LB) or they may occur years after lung
transplantation as Chronic
Lung Allograft Dysfunction (CLAD). CLAD was previously known as bronchiolitis
obliterans (BO) but now is considered a syndrome that can have different
pathological
manifestations including BO, restrictive CLAD (rCLAD or RAS) and neutrophilic
allograft
dysfunction. Chronic lung allograft dysfunction (CLAD) is a major challenge in
long-term
management of lung transplant recipients as it causes a transplanted lung to
progressively
lose functionality (Gauthier et al., Curr Transplant Rep., 2016, 3(3), 185-
191). CLAD is
poorly responsive to treatment and therefore, there remains a need for
effective compounds
capable of preventing or treating this condition. Several JAK-dependent
cytokines such as
IFNy and IL-5 are up-regulated in CLAD and lung transplant rejection
(Berastegui et al, Clin
Transplant 2017, 31, e12898). Moreover, high lung levels of CXCR3 chemokines
such as
17
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
CXCL9 and CXCL10 which are downstream of JAK-dependent IFN signaling, are
linked to
worse outcomes in lung transplant patients (Shino et al, PLOS One, 2017, 12
(7), e0180281).
Systemic JAK inhibition has been shown to be effective in kidney transplant
rejection
(Vicenti et al., American Journal of Transplantation, 2012, 12, 2446-56).
Therefore, JAK
inhibitors have the potential to be effective in treating or preventing lung
transplant rejection
and CLAD. Similar T cell activation events as described as the basis for lung
transplant
rejection also are considered the main driver of lung graft-versus-host
disease (GVHD)
which can occur post hematopoietic stem cell transplants. Similar to CLAD,
lung GVHD is a
chronic progressive condition with extremely poor outcomes and no treatments
are currently
approved. A retrospective, multicenter survey study of 95 patients with
steroid-refractory
acute or chronic GVHD who received the systemic JAK inhibitor ruxolitinib as
salvage
therapy demonstrated complete or partial response to ruxolitinib in the
majority of patients
including those with lung GVHD (Zeiser et al, Leukemia, 2015, 29, 10, 2062-
68). As
systemic JAK inhibition is associated with serious adverse events and a small
therapeutic
index, the need remains for an inhaled lung-directed, non-systemic JAK
inhibitor to prevent
and/or treat lung transplant rejection or lung GVHD.
Accordingly, the disclosure further provides a method of treating the
additional
respiratory conditions described above in a mammal, the method comprising
administering to
the mammal compound 1, or a pharmaceutically acceptable salt thereof.
Gastrointestinal inflammatory disease
As a JAK inhibitor, compound 1, or a pharmaceutical salt thereof, may also be
useful
to treat gastrointestinal inflammatory diseases that include, but are not
limited to,
inflammatory bowel disease, ulcerative colitis (proctosigmoiditis, pancolitis,
ulcerative
proctitis and left-sided colitis), Crohn's disease, collagenous colitis,
lymphocytic colitis,
Behcet's disease, celiac disease, immune checkpoint inhibitor induced colitis,
ileitis,
eosinophilic esophagitis, graft versus host disease-related colitis, and
infectious colitis.
Ulcerative colitis (Reimund et al., J Clin Immunology, 1996, 16, 144-150),
Crohn's disease
(Woywodt et al., Eur J Gastroenterology Hepatology, 1999, 11, 267-276),
collagenous
colitis (Kumawat et al., Mol Immunology, 2013, 55, 355-364), lymphocytic
colitis (Kumawat
et al., 2013), eosinophilic esophagitis (Weinbrand-Goichberg et al., Immunol
Res, 2013, 56,
249-260), graft versus host disease-related colitis (Coghill et al., Blood,
2001, 117, 3268-
18
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
3276), infectious colitis (Stallmach et al., Int J Colorectal Dis, 2004, 19,
308-315), Behcet's
disease (Zhou et al., Autoimmun Rev, 2012, 11, 699-704), celiac disease (de
Nitto et al.,
World J Gastroenterol, 2009, 15,4609-4614), immune checkpoint inhibitor
induced colitis
(e.g., CTLA-4 inhibitor-induced colitis; (Yano et al., J Translation Med,
2014, 12, 191), PD-
1- or PD-L1-inhibitor-induced colitis), and ileitis (Yamamoto et al., Dig
Liver Dis, 2008, 40,
253-259) are characterized by elevation of certain pro-inflammatory cytokine
levels. As
many pro-inflammatory cytokines signal via JAK activation, compounds described
in this
application may be able to alleviate the inflammation and provide symptom
relief.
Inflammatory skin disease
Atopic dermatitis and other inflammatory skin diseases have been associated
with
elevation of proinflammatory cytokines that rely on the JAK-STAT pathway.
Therefore
compound 1, or a pharmaceutical salt thereof, may be beneficial in a number of
dermal
inflammatory or pruritic conditions that include, but are not limited to
atopic dermatitis,
alopecia areata, vitiligo, psoriasis, dermatomyositis, cutaneous T cell
lymphoma
(Netchiporouk et al., Cell Cycle. 2014; 13, 3331-3335) and subtypes (Sezary
syndrome,
mycosis fungoides, pagetoid reticulosis, granulomatous slack skin,
lymphomatoid papulosis,
pityriasis lichenoides chronica, pityriasis lichenoides et varioliformis
acuta, CD30+
cutaneous T-cell lymphoma, secondary cutaneous CD30+ large cell lymphoma, non-
mycosis
fungoides CD30- cutaneous large T-cell lymphoma, pleomorphic T-cell lymphoma,
Lennert
lymphoma, subcutaneous T-cell lymphoma, angiocentric lymphoma, blastic NK-cell
lymphoma), prurigo nodularis, lichen planus, primary localized cutaneous
amyloidosis,
bullous pemphigoid, skin manifestations of graft versus host disease,
pemphigoid, discoid
lupus, granuloma annulare, lichen simplex chronicus, vulvariscrotaliperianal
pruritus, lichen
sclerosus, post herpetic neuralgia itch, lichen planopilaris, and foliculitis
decalvans. In
particular, atopic dermatitis (Bao et al., JAK-STAT', 2013, 2, e24137),
alopecia areata (Xing et
al., Nat Med. 2014, 20, 1043-1049), vitiligo (Craiglow et al, JAMA Dermatol.
2015, 151,
1110-1112), prurigo nodularis (Sonkoly et al., J Allergy Clin Immunol. 2006,
117, 411-417),
lichen planus (Welz-Kubiak et al., J Immunol Res. 2015, ID 854747), primary
localized
cutaneous amyloidosis (Tanaka etal., Br J Dermatol. 2009, 161, 1217-1224),
bullous
pemphigoid (Feliciani et al., Int J Immunopathol Pharmacol. 1999, 12, 55-61),
and dermal
manifestations of graft versus host disease (Okiyama et al., J Invest
Dermatol. 2014, 134,
19
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
992-1000) are characterized by elevation of certain cytokines that signal via
JAK activation.
Accordingly, compound 1, or a pharmaceutically acceptable salt thereof, may be
able to
alleviate associated dermal inflammation or pruritus driven by these
cytokines.
Other diseases
Compound 1, or a pharmaceutically acceptable salt thereof, may also be useful
to
treat other diseases such as other inflammatory diseases, autoimmune diseases
or cancers.
Compound 1, or a pharmaceutically acceptable salt thereof, may be useful to
treat one or
more of arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis,
transplant rejection,
xerophthalmia, psoriatic arthritis, diabetes, insulin dependent diabetes,
motor neurone
disease, myelodysplastic syndrome, pain, sarcopenia, cachexia, septic shock,
systemic lupus
erythematosus, leukemia, chronic lymphocytic leukemia, chronic myelocytic
leukemia, acute
lymphoblastic leukemia, acute myelogenous leukemia, ankylosing spondylitis,
myelofibrosis,
B-cell lymphoma, hepatocellular carcinoma, Hodgkins disease, breast cancer,
Multiple
myeloma, melanoma, non-Hodgkin lymphoma, non-small-cell lung cancer, ovarian
clear cell
carcinoma, ovary tumor, pancreas tumor, polycythemia vera, Sjoegrens syndrome,
soft tissue
sarcoma, sarcoma, splenomegaly, T-cell lymphoma, and thalassemia major.
Combination therapy
Compound 1 of the disclosure or a pharmaceutically acceptable salt thereof may
be
used in combination with one or more agents which act by the same mechanism or
by
different mechanisms to treat a disease. The different agents may be
administered
sequentially or simultaneously, in separate compositions or in the same
composition. Useful
classes of agents for combination therapy include, but are not limited to, a
beta 2
adrenoceptor agonist, a muscarinic receptor antagonist, a glucocorticoid
agonist, a G-protein
coupled receptor-44 antagonist, a leukotriene D4 antagonist, a muscarinic M3
receptor
antagonist, a histamine H1 receptor antagonist, an immunoglobulin E
antagonist, a PDE 4
inhibitor, an IL-4 antagonist, a muscarinic M1 receptor antagonist, a
histamine receptor
antagonist, an 1L-13 antagonist, an IL-5 antagonist, a 5-Lipoxygenase
inhibitor, a beta
adrenoceptor agonist, a CCR3 chemokine antagonist, a CFTR stimulator, an
immunoglobulin
modulator, an interleukin 33 ligand inhibitor, a PDE 3 inhibitor, a
phosphoinositide-3 kinase
delta inhibitor, a thromboxane A2 antagonist, an elastase inhibitor, a Kit
tyrosine kinase
inhibitor, a leukotriene E4 antagonist, a leukotriene antagonist, a PGD2
antagonist, a TNF
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
alpha ligand inhibitor, a 'TNF binding agent, a complement cascade inhibitor,
an eotaxin
ligand inhibitor, a glutathione reductase inhibitor, an histamine H4 receptor
antagonist, an
IL-6 antagonist, an IL2 gene stimulator, an immunoglobulin gamma Fc receptor
BB
modulator, an interferon gamma ligand, an interleukin 13 ligand inhibitor, an
interleukin 17
ligand inhibitor, a L-Selectin antagonist, a leukocyte elastase inhibitor, a
leukotriene C4
antagonist, a Leukotriene C4 synthase inhibitor, a membrane copper amine
oxidase inhibitor,
a metalloprotease-12 inhibitor, a metalloprotease-9 inhibitor, a mite allergen
modulator, a
muscarinic receptor modulator, a nicotinic acetylcholine receptor agonist, a
nuclear factor
kappa B inhibitor, a p-Selectin antagonist, a PDE 5 inhibitor, a PDGF receptor
antagonist, a
phosphoinositide-3 kinase gamma inhibitor, a TLR-7 agonist, a TNF antagonist,
an Abl
tyrosine kinase inhibitor, an acetylcholine receptor antagonist, an acidic
mammalian chitinase
inhibitor, an ACTH receptor agonist, an actin polymerization modulator, an
adenosine Ai
receptor antagonist, an adenylate cyclase stimulator, an adrenoceptor
antagonist, an
adrenocorticotrophic hormone ligand, an alcohol dehydrogenase 5 inhibitor, an
alpha 1
antitrypsin stimulator, an alpha 1 proteinase inhibitor, an androgen receptor
modulator, an
angiotensin converting enzyme 2 stimulator, an ANP agonist, a Bcr protein
inhibitor, a beta 1
adrenoceptor antagonist, a beta 2 adrenoceptor antagonist, a beta 2
adrenoceptor modulator, a
beta amyloid modulator, a BMP10 gene inhibitor, a BMP15 gene inhibitor, a
calcium
channel inhibitor, a cathepsin G inhibitor, a CCL26 gene inhibitor, a CCR3
chemokine
.. modulator, a CCR4 chemokine antagonist, a cell adhesion molecule inhibitor,
a chaperonin
stimulator, a chitinase inhibitor, a collagen T antagonist, a complement C3
inhibitor, a CSF-1
antagonist, a CXCR2 chemokine antagonist, a cytokine receptor common beta
chain
modulator, a cytotoxic T-lymphocyte protein-4 stimulator, a deoxyribonuclease
I stimulator,
a deoxyribonuclease stimulator, a dipeptidyl peptidase 1 inhibitor, a DNA
gyrase inhibitor, a
DP prostanoid receptor modulator, an E-Selectin antagonist, an EGFR family
tyrosine kinase
receptor inhibitor, an elastin modulator, an Endothelin ET-A antagonist, an
Endothelin ET-B
antagonist, an epoxide hydrolase inhibitor, a FGF3 receptor antagonist, a Fyn
tyrosine kinase
inhibitor, a GATA 3 transcription factor inhibitor, a Glucosylceramidase
modulator, a
Glutamate receptor modulator, a GM-CSF ligand inhibitor, a Guanylate cyclase
stimulator, a
H+ K+ ATPase inhibitor, an hemoglobin modulator, an Heparin agonist, an
Histone
deacetylase inhibitor, an Histone deacetylase-2 stimulator, an HMG CoA
reductase inhibitor,
21
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
an I-kappa B kinase beta inhibitor, an ICAM1 gene inhibitor, an IL-17
antagonist, an IL-17
receptor modulator, an IL-23 antagonist, an IL-4 receptor modulator, an
Immunoglobulin G
modulator, an Immunoglobulin G1 agonist, an Immunoglobulin G1 modulator, an
Immunoglobulin epsilon Fc receptor IA antagonist, an Immunoglobulin gamma Fc
receptor
IB3 antagonist, an Immunoglobulin kappa modulator, an Insulin sensitizer, an
Interferon beta
ligand, an Interleukin 1 like receptor antagonist, an Interleukin 18 ligand
inhibitor, an
Interleukin receptor 17A antagonist, an Interleukin-1 beta ligand inhibitor,
an Interleukin-5
ligand inhibitor, an Interleukin-6 ligand inhibitor, a KCNA voltage-gated
potassium
channel-3 inhibitor, a Kit ligand inhibitor, a Laminin-5 agonist, a
Leukotriene CysLT1
receptor antagonist, a Leukotriene CysLT2 receptor antagonist, a LOXL2 gene
inhibitor, a
Lyn tyrosine kinase inhibitor, a MARCKS protein inhibitor, a MDR associated
protein 4
inhibitor, a Metalloprotease-2 modulator, a Metalloprotease-9 modulator, a
Mineralocorticoid receptor antagonist, a Muscarinic M2 receptor antagonist, a
Muscarinic
M4 receptor antagonist, a Muscarinic M5 receptor antagonist, a Natriuretic
peptide receptor
A agonist, a Natural killer cell receptor modulator, a Nicotinic ACh receptor
alpha 7 subunit
stimulator, a NK cell receptor modulator, a Nuclear factor kappa B modulator,
an opioid
growth factor receptor agonist, a P-Glycoprotein inhibitor, a P2X3
purinoceptor antagonist, a
p38 MAP kinase inhibitor, a Peptidase 1 modulator, a phospholipase A2
inhibitor, a
phospholipase C inhibitor, a plasminogen activator inhibitor 1 inhibitor, a
platelet activating
factor receptor antagonist, a PPAR gamma agonist, a prostacyclin agonist, a
protein tyrosine
kinase inhibitor, a SH2 domain inositol phosphatase 1 stimulator, a signal
transduction
inhibitor, a sodium channel inhibitor, a STAT-3 modulator, a Stem cell antigen-
1 inhibitor, a
superoxide dismutase modulator, a T cell surface glycoprotein CD28 inhibitor,
a T-cell
surface glycoprotein CD8 inhibitor, a TGF beta agonist, a TGF beta antagonist,
a
thromboxane synthetase inhibitor, a thymic stromal lymphoprotein ligand
inhibitor, a
thymosin agonist, a thymosin beta 4 ligand, a TLR-8 agonist, a TLR-9 agonist,
a TLR9 gene
stimulator, a Topoisomerase IV inhibitor, a Troponin I fast skeletal muscle
stimulator, a
Troponin T fast skeletal muscle stimulator, a Type I IL-1 receptor antagonist,
a Type II TNF
receptor modulator, an ion channel modulator, a uteroglobin stimulator, and a
VIP agonist.
Specific agents that may be used in combination with the present JAK inhibitor
compound 1 include, but are not limited to rosiptor acetate, umeclidinium
bromide,
22
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
secukinumab, metenkefalin acetate, tridecactide acetate, fluticasone
propionate, alpha-
cyclodextrin-stabilized sulforaphane, tezepeltunab, mometasone furoate, BI-
1467335,
dupilumab, aclidinium, formoterol, AZD-1419, HE-1640V, rivipansel, CMP-001,
mannitol,
ANB-020, omalizumab, tregalizumab, Mitizax, benralizumab, golimumab,
roflumilast,
imatinib, REGN-3500, masitinib, apremilast, RPL-554, Actimmune, adalimumab,
rupatadine, parogrelil, MK-1029, beclometasone dipropionate, formoterol
fumarate,
mogamulizumab, seratrodast, UCB-4144, nemiralisib, CK-2127107, fevipiprant,
danirixin,
bosentan, abatacept, EC-18, duvelisib, dociparstat, ciprofloxacin, salbutamol
HFA,
erdosteine, PrEP-001, nedocromil, CDX-0158, salbutamol, enobosarm, R-TPR-022,
lenzilumab, fluticasone furoate, vilanterol trifenatate, fluticasone
propionate, salmeterol, PT-
007, PRS-060, remestemcel-L, citrulline, RPC-4046, nitric oxide, DS-102,
gerilimzumab,
Actair, fluticasone furoate, umeclidinium, vilanterol, AG-NPP709, Gamunex,
infliximab,
Ampion, acumapimod, canakinumab, INS-1007, CYP-001, sirukumab, fluticasone
propionate, mepolizumab, pitavastatin, solithromycin, etanercept, ivacaftor,
anakinra, MPC-
300-IV, glycopyrronium bromide, aclidinium bromide, FP-025, risankizumab,
glycopyrronium, formoterol fumarate, Adipocell, YPL-001, tiotropium bromide,
glycopyrronium bromide, indacaterol maleate, andecaliximab, olodaterol,
esomeprazole, dust
mite vaccine, mugwort pollen allergen vaccine, vamorolone, gefapixant,
revefenacin,
gefitinib, Rejoin, tipelukast, bedoradrine, SCM-CGH, SHP-652, RNS-60,
brodalumab, BIO-
11006, umeclidinium bromide, vilanterol trifenatate, ipratropium bromide,
tralokinumab,
PUR-1800, VX-561, VX-371, olopatadine, tulobuterol, formoterol fumarate,
triamcinolone
acetonide, reslizumab, salmeterol xinafoate, fluticasone propionate,
beclometasone
dipropionate, formoterol fumarate, tiotropium bromide, ligelizumab, RUT!,
bertilimumab,
omalizumab, glycopyrronium bromide, SENS-111, beclomethasone dipropionate, CHF-
5992, LT-4001, indacaterol, glycopyrronium bromide, mometasone furoate,
fexofenadine,
glycopyrronium bromide, azithromycin, AZD-7594, formoterol, CHF-6001,
batefenterol,
OATD-01, olodaterol, CJM-112, rosiglitazone, salmeterol, setipiprant, inhaled
interferon
beta, AZD-8871, plecanatide, fluticasone, salmeterol, eicosapentaenoic acid
monoglycerides,
lebrikizumab, RG-6149, QBKPN, Mometasone, indacaterol, AZD-9898, sodium
pyruvate,
zileuton, CG-201, imidafenacin, CNTO-6785, CLBS-03, mometasone, RGN-137,
procaterol,
formoterol, CCI-15106, POL-6014, indacaterol, beclomethasone, MV-130, GC-1112,
23
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Allergovac depot, MEDI-3506, QBW-251, ZPL-389, udenafil, GSK-3772847,
levocetirizine, AXP-1275, ADC-3680, timapiprant, abediterol, AZD-7594,
ipratropium
bromide, salbutamol sulfate, tadekinig alfa, ACT-774312, domase alfa,
iloprost,
batefenterol, fluticasone furoate, alicaforsen, ciclesonide, emeramide,
arformoterol, SB-010,
Ozagrel, BTT-1023, Dectrekumab, levalbuterol, pranlukast, hyaluronic acid, GSK-
2292767,
Formoterol, NOV-14, Lucinactant, salbutamol, prednisolone, ebastine,
dexamethasone
cipecilate, GSK-2586881, BI-443651, GSK-2256294, VR-179, VR-096, hdm-ASIT+,
budesonide, GSK-2245035, VTX-1463, Emedastine, dexpramipexole, levalbuterol, N-
6022,
dexamethasone sodium phosphate, PIN-201104, OPK-0018, TEV-48107, suplatast, BI-
1060469, Gemilukast, interferon gamma, dalazatide, bilastine, fluticasone
propionate,
salmeterol xinafoate, RP-3128, bencycloquidium bromide, reslizumab, PBF-680,
CRTH2
antagonist, Pranlukast, salmeterol xinafoate, fluticasone propionate,
tiotropium bromide
monohydrate, masilukast, RG-7990, Doxofylline, abediterol, glycopyrronium
bromide, TEV-
46017, ASM-024, fluticasone propionate, glycopyrronium bromide, salmeterol
xinafoate,
salbutamol, TA-270, Flunisolide, sodium chromoglycate, Epsi-gam, ZPL-521,
salbutamol,
aviptadil, TRN-157, Zafirlukast, Stempeucel, pemirolast sodium, nadolol,
fluticasone
propionate + salmeterol xinafoate, RV-1729, salbutamol sulfate, carbon dioxide
+
perfluorooctyl bromide, APL-1, dectrekumab + VAK-694, lysine acetylsalicylate,
zileuton,
TR-4, human allogenic adipose-derived mesenchymal progenitor cell therapy,
MEDI-9314,
PL-3994, HMP-301, TD-5471, NKTT-120, pemirolast, beclomethasone dipropionate,
trantinterol, monosodium alpha luminol, IMD-1041, AM-211, TBS-5, ARRY-502,
seratrodast, recombinant midismase, ASM-8, deflazacort, bambuterol, RBx-
10017609,
ipratropium + fenoterol, fluticasone + formoterol, epinastine, WIN-901X,
VALERGEN-
DS,OligoG-COPD-5/20, tulobuterol, oxis Turbuhaler, DSP-3025, ASM-024,
mizolastine,
budesonide + salmeterol, LH-011, AXP-E, histamine human immunoglobulin, YHD-
001,
theophylline, ambroxol + erdosteine, ramatroban, montelukast, pranlukast, AG-
1321001,
tulobuterol, ipratropium + salbutamol, tranilast, methylprednisolone
suleptanate, colforsin
daropate, repirinast, and doxofylline.
Also provided, herein, is a pharmaceutical composition comprising compound 1,
or a
pharmaceutically acceptable salt thereof and one or more other therapeutic
agents. The
therapeutic agent may be selected from the class of agents specified above and
from the list
24
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
of specific agent described above. In some embodiments, the pharmaceutical
composition is
suitable for delivery to the lungs. In some embodiments, the pharmaceutical
composition is
suitable for inhaled or nebulized administration. In some embodiments, the
pharmaceutical
composition is a dry powder or a liquid composition.
Further, in a method aspect, the invention provides a method of treating a
disease or
disorder in a mammal comprising administering to the mammal compound 1 or a
pharmaceutically acceptable salt thereof and one or more other therapeutic
agents.
When used in combination therapy, the agents may be formulated in a single
pharmaceutical composition, or the agents may be provided in separate
compositions that are
administered simultaneously or at separate times, by the same or by different
routes of
administration. Such compositions can be packaged separately or may be
packaged together
as a kit. The two or more therapeutic agents in the kit may be administered by
the same route
of administration or by different routes of administration.
The compound of the invention has been demonstrated to be a potent inhibitor
of the
JAK1, JAK2, JAK3, and TYK2 enzymes in enzyme binding assays, to have potent
functional
activity without cytotoxicity in cellular assays, and to exert the
pharmacodynamic effects of
JAK inhibition in preclinical models, as described in the following examples.
EXAMPLES
The following synthetic and biological examples are offered to illustrate the
invention, and are not to be construed in any way as limiting the scope of the
invention. In
the examples below, the following abbreviations have the following meanings
unless
otherwise indicated. Abbreviations not defined below have their generally
accepted
meanings.
ACN = acetonitrile
DCC = dicyclohexylcarbodiimide
DIPEA= N,N-diisopropylethylamine
DMF = AT,N-dimethylformamide
Et0Ac = ethyl acetate
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
HATU= N,N,N1,11P-tetramethy1-0-(7-azabenzotriazol-1-yOuronium
hexafluorophosphate
LDA = lithium diisopropylamide
min = minute(s)
MTBE = methyl tert-butyl ether
NBS = N-bromosuccinimide
RI = room temperature
THF = tetrahydrofuran
bis(pinacolato)diboron = 4,4,5,5,4',4',5',5'-octamethyl-
[2,2']bi[[1,3,2]dioxaborolanyl]
Pd(dppf)C12-CH2C12= dichloro(1,1'-bis(diphenylphosphino)-ferrocene)-
dipalladium(II) complex with dichloromethane
Reagents and solvents were purchased from commercial suppliers (Aldrich,
Fluka,
Sigma, etc.), and used without further purification. Progress of reaction
mixtures was
monitored by thin layer chromatography (TLC), analytical high performance
liquid
chromatography (anal. HPLC), and mass spectrometry. Reaction mixtures were
worked up
as described specifically in each reaction; commonly they were purified by
extraction and
other purification methods such as temperature-, and solvent-dependent
crystallization, and
precipitation. in addition, reaction mixtures were routinely purified by
column
.. chromatography or by preparative HPLC, typically using C18 or BDS column
packings and
conventional eluents. Typical preparative HPLC conditions are described below.
Characterization of reaction products was routinely carried out by mass and 1H-
NMR
spectrometry. For NMR analysis, samples were dissolved in deuterated solvent (
such as
CD30D, CDCI3, or d6-DMS0), and 111-NMR spectra were acquired with a Varian
Gemini
2000 instrument (400 MHz) under standard observation conditions. Mass
spectrometric
identification of compounds was performed by an electrospray ionization method
(ESMS)
with an Applied Biosystems (Foster City, CA) model API 150 EX instrument or a
Waters
(Milford, MA) 3100 instrument, coupled to autopurification systems.
Preparative HPLC Conditions
Column: C18, 5 gm. 21.2 x 150 mm or C18, 5 gm 21 x 250 or
C14, 5 p.m 21x150 mm
26
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Column temperature: Room Temperature
Flow rate: 20.0 mLlmin
Mobile Phases: A = Water + 0.05 % TFA
B = ACN + 0.05 % TFA,
Injection volume: (100-1500 ttL)
Detector wavelength: 214 nm
Crude compounds were dissolved in 1:1 water:acetic acid at about 50 mg/mL . A
4 minute analytical scale test run was carried out using a 2.1 x 50 mm C18
column followed
by a 15 or 20 minute preparative scale run using 1001AL injection with the
gradient based on
the % B retention of the analytical scale test run. Exact gradients were
sample dependent.
Samples with close running impurities were checked with a 21 x 250 mm C18
column and/or
a 21 x 150 mm C14 column for best separation. Fractions containing desired
product were
identified by mass spectrometric analysis.
Analytic HPLC Conditions
Method A
Column: Agilent Zorbax Bonus-RP C18, 150 x 4.60 nm, 3.5 micron
Column temperature: 40 C
Flow rate: 1.5 mLlmin
Injection volume: 51AL
Sample preparation: Dissolve in 1:1 ACN:1 M HC1
Mobile Phases: A = Water: TFA (99.95:0.05)
B = ACN:TFA (99.95:0.05)
Detector wavelength: 254 nm and 214 nm
Gradient: 26 min total (time (min)/ % B): 0/5, 18/90, 22/90, 22.5/90,
26/5
Method B
Column: Agilent Poroshell 120 Bonus-RP, 4.6 x 150 mm, 2.7 pm
Column temperature: 30 C
Flow rate: 1.5 mL/min
Injection volume: 10 pL
Mobile Phases: A = ACN:Water:TFA (2:98:0.1)
B = ACN:Water:TFA (90:10:0.1)
27
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Sample preparation: Dissolve in Mobile phase B
Detector wavelength: 254 nm and 214 nm
Gradient: 60 min total (time (min)/ % B): 0/0, 50/100, 55/100, 55.1/0,
60/0
Preparation 1 : 1-benzy1-4-imino-1,4-dihydropyridin-3-amine
HN¨cN¨Bn
H2N
A mixture of pyridine-3,4-diamine (445 g, 4.078 mol) and ACN (11.0 L) was
stirred
for 80 min from 25 C to 15 C. Benzyl bromide (485 mL, 4.078 mol) was added
over 20
min and the reaction mixture was stirred at 20 C overnight. The reaction
mixture was
cooled to 10 C and filtered. To the reactor was added ACN (3 L), which was
cooled to 10
C. The cake was washed with the reactor rinse and washed again with ACN (3 L)
warmed to
25 C. The solid was dried on the filter for 24 h under nitrogen, at 55 C
under vacuum for 2
h and then at RT overnight and for 4 d to provide the HBr salt of the title
compound (1102.2
g, 3.934 mol, 96 % yield). HPLC Method A Retention time 4.12 min.
Preparation 2 : 5-Benzy1-2-(6-bromo-1H-indazol-3-0)-5H-imidazo[4.5-
c]pyridine
Br
HN¨N
(a) 5-Benzy1-2-(6-bromo-1H-indazol-3-y1)-5H-imidazo[4,5-c]pyridine
A solution of 6-bromo-1H-indazole-3-carbaldehyde (550 g, 2.444 mol), 1-benzy1-
4-
imino-1,4-dihydropyridin-3-amine HBr (721 g, 2.333 mol) and DMAc (2.65 L) was
stirred
for 60 min and sodium bisulfite (257 g, 2.468 mol) was added. The reaction
mixture was
heated to 135 C and held for 3 h, and allowed to cool to 20 C and held at 20
C overnight.
Acetonitrile (8 L) was added and the reaction mixture was stirred for 4 h at
15 C. The slurry
was filtered on a pressure filter at medium filtration rate. To the reactor
was added ACN (1
L) The cake was washed with the ACN reactor wash and dried under nitrogen
overnight and
then under vacuum at 50 C for 24 h to provide the HBr salt of the title
compound (1264 g,
28
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
2.444 mol, 100 % yield, 94 % purity) as a dense wet beige/brown solid. HPLC
Method A
Retention time 8.77 min.
A mixture of the product of the previous step (1264 g, 2.444 mol), MeTHF (6 L)
and
water (2.75 L) was heated to 65 C and sodium hydroxide 50 wt % (254 g, 3.177
mol) was
added over 5 min and the reaction mixture was stirred at 65 C for 1 h, cooled
to RT, then to
5 C and held for 2 h. The slurry was filtered and the reactor and cake were
washed with
MeTHF (1 L). The resulting beige to yellow solid was dried on the filter under
nitrogen for 3
d to provide the title compound (475 g, 1.175 mmol, 48 % yield) as a
beige/yellow solid.
The mother liquor (about 8 L) was concentrated to about 2 L, whereupon solids
began to
crash out., The slurry was heated to 50 C, held for 2 h, cooled to 5 C over 2
h, stirred
overnight, and filtered. The cake was washed with MeTHF (100 mL) and dried
overnight
under vacuum at 40 C to provide additional title compound (140 g, 0.346 mol,
14 % yield).
A mixture of the total product of the previous step, combined with the product
of a
second batch at the same scale (1500 g, 3.710 mol) and MeTHF (4 L) was stirred
at 20 C for
2 hand filtered. The reactor and cake were washed with MeTHF (1.5 L). The
resulting
beige to yellow solid was dried under nitrogen for 3 d to provide the title
compound as a
beige yellow solid (1325 g, 3.184 mol, 86% yield (overall 68 % yield), 97%
purity). HPLC
Method A Retention time 8.77 min
Preparation 3: 5-benzy1-2-(6-bromo4H-indazol-3-y1)-4,5,6,7-tetrahydro-1H-
imidazo[4,5-clpyridine
Br
Bn
/
HN-N
To a 15 L flask was added 5-benzy1-2-(6-bromo-1H-indazol-3-y1)-5H-imidazo[4,5-
c]pyridine (440 g, 1.088 mol) followed by MeTHF (4.5 L), methanol (2.25 L) and
water
(1.125 L). The slurry was cooled to 20 C, stirred for 1 h, and NaBH4 (247 g,
6.530 mol) was
added. The reaction mixture was stirred at 25 C for 18 h. Water (1.125 L) was
added
followed by 20 wt %. sodium chloride solution (1.125 L) and the mixture was
stirred for 30
min and the layers allowed to separate. The aqueous layer was drained. A
premixed solution
of NaOH (522 g) and water (5 L) was added and the reaction mixture was stirred
for 60 min;
29
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
the layers were allowed to separate and the aqueous layer was drained. Two
additional
batches at the same scale were prepared.
The organic layer from one batch was concentrated under reduced pressure in a
15 L
jacketed reactor with the jacket set at 50 C, internal temperature 20 C. The
additional
batches were added to the reactor and concentrated one at a time resulting in
a slurry about 6
L in volume. The slurry was heated to 50 C, IPAc (6 L) was added and the
mixture was
held at 60 C for 1.5 h, cooled to 20 C for 10 h, heated to 60 C for 50 h,
cooled to 20 C in 5
h, then cooled to 5 C and held for 3 h. The mixture was filtered and the
reactor and cake
was washed with a premixed solution of1PAc (1 L) and MeTHF (1 L), precooled to
5 C.
The solids were dried under nitrogen on the filter at 40 C for 3 d to provide
the title
compound (1059 g, 2.589 mol, 79 % yield) as an off-white solid. The material
was further
dried in a vacuum oven at 50-60 C for 8 h and at 27 C for 2 d to provide the
title compound
(1043 g, 2.526 mol, 77 % yield, 99% purity). HPLC Method A Retention time 6.73
min.
Preparation 4: (4-(Benzyloxy)-2-ethyl-5-fluorophenyl)trifluoroborate,
potassium
Bn0
BF3K
(a) 2-(4-(Benzyloxy)-2-ethyl-5-fluoropheny1)-4,4,5,5-tetramethy1-1,3,2-
dioxaborolane
A mixture of 1-(benzyloxy)-4-bromo-5-ethyl-2-fluorobenzene (520 g, 1682 mmol)
and dioxane (5193 mL) was purged with nitrogen and then bis(pinacolato)diboron
(641 g,
2523 mmol) was added followed by potassium acetate (495 g, 5046 mmol). The
reaction
mixture was purged with nitrogen; Pd(dppf)C12 (41.2 g, 50.5 mmol) was added;
the reaction
mixture was purged with nitrogen, heated at 103 C under nitrogen for 5 h; and
cooled to RT.
The reaction mixture was concentrated by vacuum distillation and partitioned
between ethyl
acetate (5204 mL) and water (5212 mL). The reaction mixture was filtered
through Celite;
the organic layer was washed with brine (2606 mL) followed by solvent removal
by vacuum
distillation to provide crude product as a thick black oil (-800 g).
The crude product was dissolved in DCM (1289 mL) and purified by silica gel
chromatography (2627 g silica preslurried in hexane, eluted with 20 % ethyl
acetate in
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
hexanes (10.35 L)). Solvent was removed by vacuum distillation to yield a
light yellow oil
(600 g). HPLC Method B Retention time 33.74 min.
(b) (4-(benzyloxy)-2-ethyl-5-fluorophenyl)trifluoroborate, potassium
The product of the previous step (200 g, 561 mmol) was mixed with acetone
(1011
mL) until complete dissolution and methanol (999 mL) was added followed by
3 M potassium hydrogen difluoride (307 g, 3930 mmol) dissolved in water (1310
mL). The
reaction mixture was stirred for 3.5 h. Most of the organic solvent was
removed by vacuum
distillation. Water (759 mL) was added and the resulting thick slurry was
stirred for 30 min
and filtered. The cake was washed with water (506 mL) and the solids were
dried on the
filter for 30 min. The solids were slurried in acetone (1237 mL) and stirred
for 1 h. The
resulting slurry was filtered and the solids washed with acetone (247 mL). The
acetone
solution was concentrated by vacuum distillation, and a constant volume (2 L)
was
maintained by slow addition of toluene (2983 mL) until all acetone and water
had been
distilled. The toluene solution was distilled to a thick yellow slurry by
rotary evaporation,
during which time the products precipitated as white solids. An additional
portion of toluene
(477 mL) was added to the mixture and stirred for 1 h. The mixture was then
filtered and
rinsed with toluene (179 mL) and dried under vacuum at 50 C for 24 h to
provide the title
compound (104 g, 310 mmol, 55 % yield) as a free-flowing, fluffy, slightly off-
white solid.
HPLC Method B Retention time 27.71 min.
Preparation 5: 5-Benzy1-2-(6-(4-(benzyloxy)-2-ethy1-5-fluoropheny1)-11-/-
indazol-
3-yI)-4,5,6,7-tetra hydro-1H-imidazo[4,5-ej pyridine
Bn0
HN¨N
(a) 5-Benzy1-2-(6-(4-(benzyloxy)-2-ethy1-5-fluoropheny1)-1H-indazol-3-y1)-
4,5,6,7-
tetrahydro-1H-imiclazo[4,5-c]pyridine
A mixture of bis(pinacolato)diboron (250 g, 984 mmol) and IPA (1.88 L) was
stirred
to dissolution and then a solution of potassium hydrogen difluoride (538 g,
6.891 mol) in
water (2.31 L) was added portion-wise over 10 min. The reaction mixture was
stirred for 1 h
and filtered. The gel-like solids were slurried with water (1.33 L) until the
mixture formed a
31
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
clear hydrogel and then for another 45 min. The resulting solids/gel were
filtered, then
reslurried in acetone (1.08 L), filtered, air dried on the filter for 30 min
and dried overnight to
provide a fluffy white solid (196.7 g).
To a 5 L flask was added 5-benzy1-2-(6-bromo-111-indazol-3-y1)-4,5,6,7-
tetrahydro-
1H-imidazo[4,5-c]pyridine (135 g, 331 mmol), (4-(benzyloxy)-2-ethy1-5-
fluoropheny1)-
trifluoroborate, potassium (133 g, 397 mmol), and the white solid product of
the previous
step (40.5 g) followed by MeTHF (1.23 L) and Me0H (1.75 L). The resulting
shiny was
degassed three times with nitrogen. To the slurry was added a degassed
solution of cesium
carbonate (431 g, 1.323 mol) in water (1.35 L). The slurry was degassed twice,
Pd
(amphos)2C12 (11.71 g, 16.53 mmol) was added, the slurry was again degassed
twice and the
reaction mixture was stirred at 67 C overnight and cooled to 20 C. The layers
were
separated and back extracted with MeTHF (550 mL). The organic layers were
combined and
concentrated by rotary evaporation until solids precipitated. MeTHF (700 mL)
was added
and the reaction mixture was stirred at 65 C. The layers were separated and
the aqueous
phase back extracted with MeTHF (135 mL). The organic phases were combined and
concentrated to about 300 mL resulting in a thick orange slurry. To the slurry
was added
Me0H (270 mL) followed by 1M HCI (1.325 L) at 20 C with rapid stirring. The
reaction
mixture was stirred for 5 min and water (1 L) was added and the resulting
slurry was stirred
for I h. The solids were filtered, washed with water (150 mL), dried on the
filter for 10 min
and at 45 C under nitrogen for 16 h to provide the 2 HC1 salt of the title
compound (221.1 g,
351 mmol, 92.2 % purity) as a light yellow solid. HPLC Method B retention time
23.41
min.
Preparation 6: 5-ethy1-2-fluoro-4-(3-(4,5,6,7-tetrahydro-1H-imidazo[4,5-
c]pyridin-2-y1)-1H-indazol-6-y1)phenol
HO
/ I
HN-N
To a 1 L flask was added 5-benzy1-2-(6-(4-(benzyloxy)-2-ethy1-5-fluoropheny1)-
1 H-
indazo1-3-y1)-4,5,6,7-tetrahydro-1H-imiclazo[4,5-c]pyridine, 2 HC1 (40 g, 63.4
mmol) as a
slurry in ethanol (348 mL) and 1.25 M HCl in Me0H (101 mL) and water (17.14
mL). The
32
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
reaction mixture was degassed with nitrogen for 5 min and 10 wt %Pd/C, 50 wt%
H20 (4.05
g, 1.903 mmol) was added. The reactor was sealed, purged with Hz pressurized
to 1-2 psi.
warmed to 50 C, and the reaction mixture was stirred overnight and filtered
through Celite.
The reactor and filter were washed with methanol (100 mL).
The filtered solution was combined with the product of a second batch at the
98 mmol
scale and concentrated to 390 g. Et0Ac (2.04 L) was added slowly with stirring
and then the
solution was cooled to 5 C with stirring. Solids were filtered, washed with
Et0Ac (510 mL),
and dried overnight at 45 C under nitrogen to provide the 2 HC1 salt of the
title compound
(58 g, 80 % yield) as an off-white solid. HPLC Method B retention time 12.83
min.
Example 1: Crystalline hydrate of 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-
4-
y1)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol
HO
HN, N
To a 3 L flask was added NMP (239 mL) and 5-ethyl-2-fluoro-4-(3-(4,5,6,7-
tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol, 2 HCl (74.5
g,
165 mmol) with stirring followed by NMP (74 mL). Acetic acid (31.3 mL) was
added and
the reaction mixture was warmed to 55 C for 10 min and then cooled to 25 C.
1-methylpiperidin-4-one (61.0 mL, 496 mmol) was added in a single portion and
the reaction
mixture was stirred at 25 C for 30 min and cooled to 15 C. Sodium
triacetoxyborohydride
(98 g, 463 mmol) was added and the external jacket was set to 20 C after 5
min. After 3 h,
ammonium hydroxide (365 mL, 5790 mmol) was added dropwise over 45 min
maintaining
the temperature below 25 C. The reaction mixture was stirred for 1.5 h at 20
C, forming an
off-white slurry. Methanol (709 mL) was added and the reaction mixture was
stirred slowly
overnight at 55 C. Water (1.19 L) was added over 30 min at 55 C and the
mixture was
cooled to 10 C, stirred for 2 h, and filtered. The cake was washed with 1:1
MeOH:water
(334 mL), dried on the filter for 20 min and at 45 C under vacuum with
nitrogen bleed to
provide yellow solids (87 g).
33
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
To the solids was added 5 % water/acetone (1.5 L) at 55 C with slow stirring
and the
reaction mixture was heated at 55 C for 6 h, cooled to 10 C, filtered, and
washed with 5 %
water/acetone (450 mL). The solids were dried overnight at 50 C under vacuum
with
nitrogen bleed, equilibrated in air for 20 h, dried in the vacuum oven for 48
h and
equilibrated with air to provide the title compound (71.3 g, 91 % yield) as a
free flowing pale
yellow solid. HPLC Method B Retention time 12.29 min.
Example 2: Powder X-Ray Diffraction
The powder X-ray diffraction (PXRD) pattern of the product of Example 1 was
obtained with a Bruker D8-Advance X-ray diffractometer using Cu-Ka radiation
(2%, = 1.54051 A) with output voltage of 45 kV and current of 40 mA. The
instrument was
operated in Bragg-Brentano geometry with incident, divergence, and scattering
slits set to
maximize the intensity at the sample. For measurement, a small amount of
powder
(5-25 mg) was gently pressed onto a sample holder to form a smooth surface and
subjected to
X-ray exposure. The samples were scanned in 20-20 mode from 2 to 40 in 20
with a step
size of 0.02 and a scan speed of 0.30'seconds per step. The data acquisition
was controlled
by Bruker DiffracSuite measurement software and analyzed by Jade software
(version 7.5.1).
The instrument was calibrated with a corundum standard, within -0.02 two-
theta angle.
Observed PXRD two-theta peak positions and d-spacings are shown in Tablel.
Table 1: PXRD Data for the Crystalline Hydrate
2-Theta d(A) Area A%
6.20 14.24 81639 45.70
9.58 9.22 178629 100.00
10.34 8.55 30022 16.80
10.65 8.30 12801 7.20
11.54 7.66 27220 15.20
12.77 6.93 27705 15.50
13.01 6.80 48785 27.30
13.39 6.61 9261 5.20
16.94 5.23 40031 22.40
17.53 5.05 83718 46.90
34
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
18.67 4.75 9542 5.30
19.28 4.60 152922 85.60
20.02 4.43 22391 12.50
20.61 4.31 30308 17.00
21.51 4.13 92875 52.00
22.10 4.02 37495 21.00
22.79 3.90 13802 7.70
23.22 3.83 12117 6.80
25.16 3.54 13792 7.70
28.80 3.10 14487 8.10
29.62 3.01 14810 8.30
30.20 2.96 9709 5.40
Biological Assays
5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-y1)-4,5,6,7-tetrahydro-1H-
imidazo[4,5-
c]pyridin-2-y1)-1H-indazol-6-yl)phenol (compound 1) has been characterized in
the
following biological assays.
Assay 1: Biochemical JAK Kinase Assays
A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were
carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01% Brij-
35, 10 mM
MgCl2, and 1 mM EGTA). Recombinant GST-tagged JAK enzymes and a GFP-tagged
STAT1 peptide substrate were obtained from Life Technologies.
The serially diluted compound was pre-incubated with each of the four JAK
enzymes
and the substrate in white 384-well microplates (Corning) at ambient
temperature for lh.
ATP was subsequently added to initiate the kinase reactions in 10 pi. total
volume, with 1%
DMSO. The final enzyme concentrations for JAK1, 2, 3 and Tyk2 are 4.2 nM, 0.1
nM, 1 nM,
and 0.25 nM respectively; the corresponding Km ATP concentrations used are 25
p.M, 3 pM,
1.6 p,M, and 10 M; while the substrate concentration is 200 nM for all four
assays. Kinase
reactions were allowed to proceed for 1 hour at ambient temperature before a
10 pL
preparation of EDTA (10mM final concentration) and Tb-anti-pSTAT1 (pTyr701)
antibody
(Life Technologies, 2 nM final concentration) in TR-FRET dilution buffer (Life
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Technologies) was added. The plates were allowed to incubate at ambient
temperature for lh
before being read on the EnVision reader (Perkin Elmer). Emission ratio
signals
(520mn/495nm) were recorded and utilized to calculate the percent inhibition
values based
on DMSO and background controls.
For dose-response analysis, percent inhibition data were plotted vs. compound
concentrations, and IC50 values were determined from a 4-parameter robust fit
model with
the Prism software (GraphPad Software). Results were expressed as pIC50
(negative
logarithm of IC50) and subsequently converted to pKi (negative logarithm of
dissociation
constant, Ki) using the Cheng-Prusoff equation.
The compound of the invention exhibited the following enzyme potency.
Table 2
UK 1 MK 2 JAI< 3 Tyk2
pKi pKa pKi pKi
10.2 10.8 9.7 9.8
Assay 2: Cellular JAK Potency Assay: Inhibition of IL-13
The AlphaScreen JAM cellular potency assay was carried out by measuring
interleukin-13 (IL-13, R&D Systems) induced STAT6 phosphorylation in BEAS-2B
human
lung epithelial cells (ATCC). The anti-STAT6 antibody (Cell Signaling
Technologies) was
conjugated to AlphaScreen acceptor beads (Perkin Elmer), while the anti-pSTAT6
(pTyr641)
antibody (Cell Signaling Technologies) was biotinylated using EZ-Link Sulfo-
NHS-Biotin
(Thermo Scientific).
BEAS-2B cells were grown at 37 C in a 5% CO2 humidified incubator in 50%
DMEM/50% F-12 medium (Life Technologies) supplemented with 10% FBS (Hyclone),
100
U/mL penicillin, 100 tig/mL streptomycin (Life Technologies), and 2 mM
GlutaMAX (Life
Technologies). On day 1 of the assay, cells were seeded at a 7,500 cells/well
density in white
poly-D-lysine-coated 384-well plates (Corning) with 25gL medium, and were
allowed to
adhere overnight in the incubator. On day 2 of the assay, the medium was
removed and
replaced with 121.11, of assay buffer (Hank's Balanced Salt Solution/HBSS,
25mM HEPES,
and 1 mg/ml bovine serum albumin/BSA) containing dose-responses of test
compounds. The
compound was serially diluted in DMSO and then diluted another 1000-fold in
media to
36
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
bring the final DMSO concentration to 0.1%. Cells were incubated with test
compounds at
37 C for 1 h, and followed by the addition of 12 pi of pre-warmed IL-13 (80
ng/mL in assay
buffer) for stimulation. After incubating at 37 C for 30 min, the assay buffer
(containing
compound and IL-13) was removed, and 10 pL of cell lysis buffer (25 mM HEPES,
0.1 %
SDS, 1 % NP-40, 5 iriM MgCl2, 1.3 iriM EDTA, 1 mM EGTA, and supplement with
Complete Ultra mini protease inhibitors and PhosSTOP from Roche Diagnostics).
The plates
were shaken at ambient temperature for 30min before the addition of detection
reagents. A
mixture of biotin-anti-pSTAT6 and anti-STAT6 conjugated acceptor beads was
added first
and incubated at ambient temperature for 2h, followed by the addition of
streptavidin
conjugated donor beads (Perkin Elmer). After a minimum of 2 h incubation, the
assay plates
were read on the EnVision plate reader. AlphaScreen luminescence signals were
recorded
and utilized to calculate the percent inhibition values based on DMSO and
background
controls.
For dose-response analysis, percent inhibition data were plotted vs. compound
concentrations, and IC50 values were determined from a 4-parameter robust fit
model with the
Prism software. Results may also be expressed as the negative logarithm of the
IC50 value,
pIC5o. The compound of the invention exhibited a pIC50 value of 8.2 in this
assay.
Assay 3: Cellular JAK Potency Assay: Inhibition of IL-2/anti-CD3 Stimulated
IFNy in human PBMCs
The potency of the test compound for inhibition of interleukin-2 (IL-2)/anti-
CD3
stimulated interferon gamma (IFNT) was measured in human peripheral blood
mononuclear
cells (PBMCs) isolated from human whole blood (Stanford Blood Center). Because
1L-2
signals through JAK, this assay provides a measure of JAK cellular potency.
(1) Human peripheral blood mononuclear cells (PBMC) were isolated from human
whole blood of healthy donors using a ficoll gradient Cells were cultured in a
37 C, 5 %
CO2 humidified incubator in RPM1 (Life Technologies) supplemented with 10 %
Heat
Inactivated Fetal Bovine Serum (FBS, Life Technologies), 2 mM Glutamax (Life
Technologies), 25 mM HEPES (Life Technologies) and 1X Pen/Strep (Life
Technologies).
Cells were seeded at 200,000 cells/well in media (50 pi) and cultured for 1 h.
Compounds
were serially diluted in DMSO and then diluted another 500-fold (to a 2x final
assay
concentration) in media. Test compounds (100 gL/well) were added to cells, and
incubated at
37
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
37 C, 5 % CO2 for 1 h, followed by the addition of IL-2 (R&D Systems; final
concentration
100 ng/mL) and anti-CD3 (BD Biosciences; final concentration 1 pg/mL) in pre-
warmed
assay media (50 L) for 24 h.
(2) After cytokine stimulation, cells were centrifuged at 500 g for 5 min and
supernatants removed and frozen at -80 C. To determine the inhibitory potency
of the test
compound in response to IL-2/anti-CD3, supernatant IFNI, concentrations were
measured via
ELISA (R&D Systems). IC50 values were determined from analysis of the
inhibition curves
of concentration of IFNy vs compound concentration. Data are expressed as
pICso (negative
decadic logarithm IC50) values. The compound of the invention exhibited a
pIC50 value of
about 7.3 in this assay.
Assay 4: Cellular JAK Potency Assay: Inhibition of IL-2 Stimulated pSTAT5 in
CD4+ 'I' cells
The potency of the test compound for inhibition of interleukin-2 (IL-2)/anti-
CD3
stimulated STAT5 phosphorylation was measured in CD4-positive (CD4+) T cells
in human
peripheral blood mononuclear cells (PBMCs) isolated from human whole blood
(Stanford
Blood Center) using flow cytometry. Because IL-2 signals through JAK, this
assay provides
a measure of JAK cellular potency.
CD4+ T cells were identified using a phycoerythrobilin (PE) conjugated anti-
CD4
antibody (Clone RPA-T4, BD Biosciences), while an Alexa Fluor 647 conjugated
anti-
pSTAT5 antibody (pY694, Clone 47, BD Biosciences) was used to detect STAT5
phosphorylation.
(1) The protocol of Assay 3 paragraph (1) was followed with the exception that
the
cytokine stimulation with anti-CD3 was performed for 30 min instead of 24 h.
(2) After cytokine stimulation, cells were fixed with pre warmed fix solution
(200 L;
BD Biosciences) for 10 min at 37 C, 5 % CO2, washed twice with DPBS buffer (1
mL, Life
Technologies), and resuspended in ice cold Perm Buffer III (1000 L, BD
Biosciences) for
min at 4 C. Cells were washed twice with 2 % FBS in DPBS (FACS buffer), and
then
resuspended in FACS buffer (100 pt) containing anti-CD4 PE (1:50 dilution) and
anti-CD3
anti-CD3Alexa Fluor 647 (1:5 dilution) for 60 min at room temperature in the
dark. After
30 incubation, cells were washed twice in FACS buffer before being analyzed
using a LSRII
flow cytometer (BD Biosciences). To determine the inhibitory potency of test
compounds in
38
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
response to IL-2/anti-CD3, the median fluorescent intensity (MFI) of pSTAT5
was measured
in CD4+ T cells. IC50 values were determined from analysis of the inhibition
curves of MFI
vs compound concentration. Data are expressed as pIC50 (negative decadic
logarithm IC50)
values. The compound of the invention exhibited a pIC5ovalue of about 7.7 in
this assay.
Assay 5: Cellular JAK Potency Assay: Inhibition of IL-4 Stimulated pSTAT6 in
CD3+ T cells
The potency of the test compound for inhibition of interleukin-4 (IL-4)
stimulated
STAT6 phosphorylation was measured in CD3-positive (CD3+) T cells in human
peripheral
blood mononuclear cells (PBMCs) isolated from human whole blood (Stanford
Blood
Center) using flow cytometry. Because IL-4 signals through JAK, this assay
provides a
measure of JAK cellular potency.
CD3+ T cells were identified using a phycoerythrobilin (PE) conjugated anti-
CD3
antibody (Clone UCHT1, BD Biosciences), while an Alexa Fluor 647 conjugated
anti-
pSTAT6 antibody (pY641, Clone 18/P, BD Biosciences) was used to detect STAT6
phosphorylation.
Human peripheral blood mononuclear cells (PBMC) were isolated from human whole
blood of healthy donors as in Assays 3 and 4. Cells were seeded at 250,000
cells/well in
media (200 pL), cultured for 1 h and then resuspended in assay media (50 pt.)
(RPMT
supplemented with 0.1% bovine serum albumin (Sigma), 2mM Glutamax, 25mM HEPES
and 1X Penstrep) containing various concentrations of test compounds.
Compounds were
serially diluted in DMSO and then diluted another 500-fold (to a 2x final
assay
concentration) in assay media. Test compounds (50 pL) were incubated with
cells at 37 C,
5% CO.) for 1 h, followed by the addition of IL-4 (50 pL) (R&D Systems; final
concentration
20 ng/mL) in pre-warmed assay media for 30 min. After cytokine stimulation,
cells were
fixed with pre-warmed fix solution (100 pL) (BD Biosciences) for 10 min at 37
C, 5% CO2,
washed twice with FACS buffer (1 mL) (2% FBS in DPBS), and resuspended in ice
cold
Perm Buffer III (1000 tit) (BD Biosciences) for 30 min at 4 C. Cells were
washed twice
with FACS buffer, and then resuspended in FACS buffer (100 pL) containing anti-
CD3 PE
(1:50 dilution) and anti-pSTAT6 Alexa Fluor 647(1:5 dilution) for 60 min at
room
temperature in the dark. After incubation, cells were washed twice in FACS
buffer before
being analyzed using a LSRII flow cytometer (BD Biosciences).
39
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
To determine the inhibitory potency of the test compound in response to IL-4,
the
median fluorescent intensity (WI) of pSTAT6 was measured in CD3+ T cells. ICso
values
were determined from analysis of the inhibition curves of MFI vs compound
concentration.
Data are expressed as pICso (negative decadic logarithm ICso). The compound of
the
invention exhibited a piCso value of 8.1 in this assay.
Assay 6: Cellular JAK Potency Assay: Inhibition of IL-6 Stimulated pSTAT3 in
CD3+ T cells
A protocol analogous to that of Assay 5 was used to determine the potency of
the test
compound for inhibition of interleuken-6 (IL-6) stimulated STAT3
phosphorylation. An
Alexa Fluor 647 conjugated anti-pSTAT3 antibody (pY705, Clone 4/P, BD
Biosciences) was
used to detect STAT3 phosphorylation.
The compound of the invention exhibited a pICso value of 7.4 in this assay.
Assay 7: Cellular JAK Potency Assay: Inhibition of IFNy-Induced pSTAT1
The potency of the test compound for inhibition of interferon gamma (1F1=17)
stimulated STAT1 phosphorylation was measured in CD14-positive (CD14+)
monocytes
derived from human whole blood (Stanford Blood Center) using flow cytometry.
Because
IFNI, signals through JAK, this assay provides a measure of JAK cellular
potency.
Monocytes were identified using a fluorescein isothiocyanate (FITC) conjugated
anti-
CD14 antibody (Clone RM052, Beckman Coulter), and an Alexa Fluor 647
conjugated anti-
pSTAT1 antibody (pY701, Clone 4a, BD Biosciences) was used to detect STAT1
phosphorylation.
Human peripheral blood mononuclear cells (PBMC) were isolated from human whole
blood of healthy donors using a ficoll gradient Cells were cultured in a 37
C, 5 % CO2
humidified incubator in RPM1 (Life Technologies) supplemented with 10 % Fetal
Bovine
Serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES
(Life
Technologies) and 1X Pen/Strep (Life Technologies). Cells were seeded at
250,000
cells/well in media (200 pL), cultured for 2 h and resuspended in assay media
(50 ii,L)
(RPMI supplemented with 0.1 % bovine serum albumin (Sigma), 2 mM Glutamax, 25
mM
HEPES and 1X Penstrep) containing various concentrations of test compounds.
The
compound was serially diluted in DMSO and then diluted another 1000-fold in
media to
bring the final DMSO concentration to 0.1 %. Test compound dilutions were
incubated with
CA 03059785 2019-10-10
WO 2018/204233
PCT/US2018/030140
cells at 37 C, 5 % CO2 for 1 h, followed by the addition of pre-warmed IFNy
(R&D
Systems) in media (50 L) at a final concentration of 0.6 ng/mL for 30 min.
After cytokine
stimulation, cells were fixed with pre-warmed fix solution (100 L) (BD
Biosciences) for 10
min at 37 C, 5 % CO2, washed twice with FACS buffer (1 mL) (1% BSA in PBS),
resuspended in 1:10 anti-CD14 FITC:FACS buffer (100 L), and incubated at 4 C
for
min. Cells were washed once, and then resuspended in ice cold Penn Buffer ifi
(BD
Biosciences) (100 L) for 30 min at 4 C. Cells were washed twice with FACS
buffer, and
then resuspended in 1:10 anti-pSTAT1 Alexa Fluor 647:FACS buffer (100 L) for
30 min at
RT in the dark, washed twice in FACS buffer, and analyzed using a LSRII flow
cytometer
10 (BD Biosciences).
To determine the inhibitory potency of the test compound, the median
fluorescent
intensity (MFI) of pSTAT1 was measured in CD14+ monocytes. IC50 values were
determined from analysis of the inhibition curves of NT' vs compound
concentration. Data
are expressed as pIC50 (negative decadic logarithm IC50) values The compound
of the
15 invention exhibited a pIC50 value of about 7.5 in this assay.
Assay 8: Ocular Pharmacokinetics in Rabbit Eyes
The objective of this assay was to determine the pharrnacokinetics of the test
compound in rabbit ocular tissues.
Solution formulation
The compound of the invention, 5-ethy1-2-fluoro-4-(3-(5-(1-methylpiperidin-4-
y1)-
4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-y1)-1H-indazol-6-yl)phenol (1)
was dissolved
in either 10 % 2-hydroxypropy1-13-cyclodextrin to attain a target
concentration of 4 mg/mL or
in purified water to attain a target concentration of 1 mg/mL . Bilateral
intravitreal injection
(50 Lleye) of the solution of test compound was administered to New Zealand
white rabbits
in two dose groups, 200 g/eye and 50 g/eye, respectively, for the
cyclodextrin and water
vehicle formulations, respectively. The test compound concentration was
measured in ocular
tissues: vitreous, aqueous, retinakhoroid and iris-ciliary body at pre-
determined time points
post injection (30 min, 4 h, 1 d, 3 d, 7 d, 14 d). Two rabbits (four eyes)
were dosed for each
time point. In the vitreous tissue, compound 1 exhibited a two-phase decrease
in
concentration characterized by an initial decrease in concentration with a
half-life of
approximately 12 hours and finally a terminal half-life of approximately 3.6
days. The
41
CA 03059785 2019-10-10
WO 2018/204233
PCT/US2018/030140
compound was found to distribute quickly into the retinal and choroidal region
as well and
shows a similar pharmacokinetic profile as in the vitreous tissue.
Suspension formulation
A suspension formulation was prepared by combining crystalline compound 1 of
Example 1 with 0.5 % hydroxypropyl methylcellulose (HPMC E5) + 0.02 % Tween 80
to
attain a target concentration of 10 mg/mL. Bilateral intravitreal injection
(50 pL/eye) of the
suspension of test compound was administered to New Zealand white rabbits (500
jig/eye).
The test compound concentration was measured in ocular tissues as in the
suspension
formulation assay at 30 min, 2 wks, 4 wks, 6 wks, and 8 wks post injection.
The compound
showed a linear decrease in drug concentration in the vitreous from 30 min to
6 weeks with a
clearance rate of approximately 3 pg/mL/day. The behavior is consistent with
the solubility
of compound 1 in the vehicle and the ocular pharmacokinetic behavior in the
solution
formulation. The drug concentration in plasma was measured and found to be at
least 3
orders of magnitude lower than the concentration in vitreous tissue
Assay 9: Pharmacodynamic Assay: Inhibition of I16-induced pSTAT3 in Rats
The ability of a single intravitreal administration of test compound to
inhibit IL-6
induced pSTAT3 was measured in rat retina/choroid homogenates.
Suspension formulations were prepared by combining crystalline compound 1 of
Example 1 with 0.5 % hydroxypropyl methylcellulose (HPMC E5 LV), 0.02 % Tween
80,
and 0.9 % sodium chloride in purified water to attain target concentrations of
3 mg/mL and
10 mg/mL.
Female Lewis rats were intravitreally (IVT) dosed (5 j.tL per eye) with the
suspension
formulations or with the drug vehicle. Three days later, IL-6 (Peprotech; 0.1
mg/mL; 5 !IL
per eye) or vehicle was intravitreally administered to induce pSTAT3. Ocular
tissues were
dissected one hour after the second IVT injection with IL-6. The
retina/choroid tissues were
homogenized and pSTAT3 levels were measured using an ELISA (Cell Signaling
Technology). The percent inhibition of IL-6-induced pSTAT3 was calculated in
comparison
to the vehicle/vehicle and vehicle/IL-6 groups. Inhibition of greater than 100
% reflects a
reduction of pSTAT3 levels to below those observed in the vehicle/vehicle
group.
42
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
With a 3 day pre-treatment prior to IL-6 challenge, the 15 gg dose and the 50
gg dose
of the compound of the invention administered by the suspension formulation
inhibited IL-6-
induced pSTAT3 by 33 % and 109 %, respectively in the retina/choroid tissues.
Assay 10: Pharmacodynamic Assay: Inhibition of IFNy-induced IP-10 in Rabbits
The ability of a single intravitreal administration of test compound to
inhibit
interferon-gamma (IFN7) induced IP-10 protein levels was measured in rabbit
vitreous and
retinalchoroid tissues.
Solution formulations at concentrations of 1 mg/mL and 4 mg/mL of compound 1
of
Example 1 were prepared as in Assay 8. A suspension formulation was prepared
by
combining crystalline compound 1 of Example 1 with 0.5 % hydroxypropyl
methylcellulose
(HPMC E5), 0.02 % Tween 80, and 9 mg/mL sodium chloride in purified water to
attain a
target concentration of 20 mg/mL.
Male, New Zealand White rabbits (Liveon Biolabs, India) were used for the
studies.
Animals were acclimated after arrival at the research facilities (Jubilant
Biosys Ltd., India).
Each rabbit was given a total of two intravitreal (TVT) injections with a
total dose volume of
50 gL per eye. The first WT injection (45 gL per eye) delivered test compound
or vehicle at
a prescribed time point (i.e. 24 hours for the solution formulations or 1 week
for the
suspension formulation). The second TVT injection (5 gL per eye) delivered
IFN7 (1 gg/eye;
Stock solution 1 mg/mL; Kingfisher Biotech) or vehicle for the induction of IP-
10. In brief,
on the day of the injections, rabbits were anesthetized with an intramuscular
injection of
ketamine (35 mg/kg) and xylazine (5 mg/kg). Once deeply anesthetized, each eye
was rinsed
with sterile saline and IVT injections were performed using a 0.5 mL insulin
syringe (50
units=0.5 mL) with a 31-gauge needle at the supra-nasal side of the both eyes
by marking the
position with a Braunstein fixed caliper (2 3/4") 3.5 mm from the rectus
muscle and 4 mm
from the limbus.
Tissues were collected 24 hours after the second IVT injection with IFN7.
Vitreous
humor (VH) and retina/choroid tissues (R/C) were collected and homogenized,
and EP-10
protein levels were measured using a rabbit CXCL10 (IP-10) ELISA kit
(Kingfisher
Biotech). The percent inhibition of IFN7-induced IP-10 was calculated in
comparison to the
vehicle/vehicle and vehicle/IFN7 groups.
43
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
When dosed as a solution, with a 24 hour pre-treatment prior to the IFNI,
challenge,
45 i.tg of compound 1 inhibited IF1=17-induced IP-10 by 70% and 86% in the
vitreous humor
and retinaichoroid tissue, respectively, while 180 jig of the compound
inhibited IFNI,-
induced IP-10 by 91% and 100% in the vitreous humor and retinalchoroid tissue,
respectively.
With a 1 week pre-treatment prior to the IFNy challenge, the crystalline
suspension
formulation of compound 1 inhibited IFIsTy-induced IP-10 by 100% in both the
vitreous
humor and retinaichoroid tissues.
Assay 11: Pharmacokinetics in Plasma and Lung in Mouse
Plasma and lung levels of the test compound and the ratio thereof was
determined in
the following manner. BALB/c mice from Charles River Laboratories were used in
the
assay. Test compounds were individually formulated in 20% propylene glycol in
pH 4
citrate buffer at a concentration of 0.2 mg/mL and 50 uL of the dosing
solution was
introduced into the trachea of a mouse by oral aspiration. At various time
points (typically
0.167, 2, 6, 24hr) post dosing, blood samples were removed via cardiac
puncture and intact
lungs were excised from the mice. Blood samples were centrifuged (Eppendorf
centrifuge,
5804R) for 4 minutes at approximately 12,000 rpm at 4 C to collect plasma.
Lungs were
padded dry, weighed, and homogenized at a dilution of 1:3 in sterile water.
Plasma and lung
levels of test compound were determined by LC-MS analysis against analytical
standards
constructed into a standard curve in the test matrix. A lung to plasma ratio
was determined as
the ratio of the lung AUC in jig hr/g to the plasma AUC in 1.1g hr/mL, where
AUC is
conventionally defined as the area under the curve of test compound
concentration vs. time.
The compound of the invention exhibited exposure in lung about 55 times
greater
than exposure in plasma in mouse.
Assay 12: Murine (Mouse) model of IL-13 induced pSTAT6 induction in lung
tissue
11-13 is an important cytokine underlying the pathophysiology of asthma
(Kudlacz et
al. Eur. J. Pharmacol, 2008, 582,154-161). IL-13 binds to cell surface
receptors activating
members of the Janus family of kinases (JAK) which then phosphorylate STAT6
and
subsequently activates further transcription pathways. In the described model,
a dose of IL-
44
CA 03059785 2019-10-10
WO 2018/204233
PCT/US2018/030140
13 was delivered locally into the lungs of mice to induce the phosphorylation
of STAT6
(pSTAT6) which is then measured as the endpoint.
Adult balb/c mice from Harlan were used in the assay. On the day of study,
animals
were lightly anesthetized with isoflurane and administered either vehicle or
test compound
(0.5 mg/mL, 501AL total volume over several breaths) via oral aspiration.
Animals were
placed in lateral recumbency post dose and monitored for full recovery from
anesthesia
before being returned to their home cage. Four hours later, animals were once
again briefly
anesthetized and challenged with either vehicle or IL-13 (0.03 p.g total dose
delivered, 50 I.LL
total volume) via oral aspiration before being monitored for recovery from
anesthesia and
returned to their home cage. One hour after vehicle or IL-13 administration,
lungs were
collected for both pSTAT6 detection using an anti-pSTAT6 ELISA (rabbit mAb
capture/coating antibody; mouse mAb detection/report antibody: anti-pSTAT6-
pY641;
secondary antibody: anti-mouse IgG-HRP) and analyzed for total drug
concentration as
described above in Assay 11.
Activity in the model is evidenced by a decrease in the level of pSTAT6
present in
the lungs of treated animals at 5 hours compared to the vehicle treated, IL-13
challenged
control animals. The difference between the control animals which were vehicle-
treated, IL-
13 challenged and the control animals which were vehicle-treated, vehicle
challenged
dictated the 0% and 100% inhibitory effect, respectively, in any given
experiment. The
compound of the invention exhibited about 60 % inhibition of STAT6
phosphorylation at
4 hours after IL-13 challenge.
Assay 13: Murine model of Alternaria allernala-induced eosinophilic
inflammation of the lung
Airway eosinophilia is a hallmark of human asthma. Alternaria alternata is a
fungal
aeroallergen that can exacerbate asthma in humans and induces eosinophilic
inflammation in
the lungs of mice (Havaux et al. Clin Exp Immunol. 2005, 139(2):179-88). In
mice, it has
been demonstrated that altemaria indirectly activates tissue resident type 2
innate lymphoid
cells in the lung, which respond to (e.g. IL-2 and IL-7) and release JAK-
dependent cytokines
(e.g. IL-5 and IL-13) and coordinate eosinophilic inflammation (Bartemes et
al. J Immunol.
2012, 188(3):1503-13).
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
Seven- to nine-week old male C57 mice from Taconic were used in the study. On
the
day of study, animals were lightly anesthetized with isoflurane and
administered either
vehicle or test compound (0.1 ¨ 1.0 mg/mL, 50 tiL total volume over several
breaths) via
oropharyngeal aspiration. Animals were placed in lateral recumbency post dose
and
monitored for full recovery from anesthesia before being returned to their
home cage. One
hour later, animals were once again briefly anesthetized and challenged with
either vehicle or
alternaria extract (200 ug total extract delivered, 500, total volume) via
oropharyngeal
aspiration before being monitored for recovery from anesthesia and returned to
their home
cage. Forty-eight hours after alternaria administration, bronchoalveolar
lavage fluid (BALF)
was collected and eosinophils were counted in the BALF using the Advia 120
Hematology
System (Siemens).
Activity in the model is evidenced by a decrease in the level of eosinophils
present in
the BALF of treated animals at forty-eight hours compared to the vehicle
treated, alternaria
challenged control animals. Data are expressed as percent inhibition of the
vehicle treated,
alternaria challenged BALF eosinophils response. To calculate percent
inhibition, the
number of BALF eosinophils for each condition is converted to percent of the
average
vehicle treated, alternaria challenged BALF eosinophils and subtracted from
one-hundred
percent. The compound of the invention exhibited about 88 % inhibition of BALF
eosinophil counts at forty-eight hours after alternaria challenge.
Assay 14: Murine model of LPS/G-CSF/IL-6/IFNy cocktail-induced airway
neutrophilic inflammation of the lung model
Airway neutrophilia is a hallmark of a range of respiratory disease in humans.
Compound 1 was tested in a model of neutrophilic airway inflammation using a
LPS/G-
CSF/IL-6/TFN7 cocktail to induce airway neutrophilia.
Seven- to nine-week old male Balb/C (wildtype) mice from Jackson Laboratory
were
used in the study. On the day of study, animals were lightly anesthetized with
isoflurane and
administered either vehicle or test compound (1.0 mg/mL, 501AL total volume
over several
breaths) via oropharyngeal aspiration. Animals were placed in lateral
recumbency post dose
and monitored for full recovery from anesthesia before being returned to their
home cage.
One hour later, animals were once again briefly anesthetized and challenged
with either
vehicle or LPS; 0.01 mg/kg/G-CSF; 5 ttg/IL-6; 511g/IFI\17; 5 ttg (100 i.tL
total volume) via
46
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
oropharyngeal aspiration (OA). Twenty-four hours after the LPS/G-CSF/11,-
6/IFNT cocktail
administration, bronchoalveolar lavage fluid (BALF) was collected and
neutrophils were
counted.
Upon OA treatment with compound 1, there was a statistically significant
reduction
of the airway neutrophils (84% compared to vehicle treated mice),
demonstrating that the
blockade of JAK-dependent signaling has effects on neutrophilic airway
inflammation.
Assay 15: Inhibition of IFNy and I1-27 induced chemokines CXCL9 and
CXCL10 in human 3D airway cultures
EpiAirway tissue cultures were obtained from Matt& (AIR-100). Cultures were
derived from asthmatic donors. In a cell culture insert, human derived
tracheal/bronchial
epithelial cells were grown and differentiated on a porous membrane support,
allowing an
air-liquid interface with warmed culture medium below the cells and a gaseous
test
atmosphere above. Tissues were cultured in maintenance media (Mattek, AIR-100-
MM) in a
37 C, 5% CO2 humidified incubator. Four donors were tested. On Day 0, tissue
cultures
were treated with test compounds at 10 M, 1 M and/or 0.1 M. Compounds were
diluted in
dimethyl sulfoxide (DMSO, Sigma) to a final concentration of 0.1%. DMSO at
0.1% was
used as a vehicle control. Test compounds were incubated with cultures for 1
hour at 37 C,
5% CO2, followed by the addition of pre-warmed media containing IFNT (R&D
Systems) or
IL-27 (R&D Systems) at a final concentration at 10Ong/ml. Tissue cultures were
maintained
for 8 days. Media was replaced every 2 days with fresh media containing
compounds and
IF1\11, or IL-27. On Day 8, tissue cultures and supernatants were collected
for analysis.
Supernatant samples were assayed for CXCL10 (1P-10) and CXCL9 (MIG) using
luminex
analysis (EMD Millipore). Data is expressed as % Inhibition +/- standard
deviation
( S'TDV). Percent inhibition was determined by compound inhibitory potency
against IFNI,
or 1L-27 induced CXCL10 or CXCL9 secretion compared to vehicle treated cells.
Data is the
average from 3 or 4 donors. Compound 1 was able to inhibit IFNI, induced
CXCL10
secretion by 99% 2.0 (at 10 M), 71% 19 (at 1.1M) and 17% 12 (at 0.1 M) when
compared to vehicle control. Compound 1 was able to inhibit IFNI, induced
CXCL9
secretion by 100% 0.3 (at 10 M), 99% -0.9 (at 1 M) and 74% 17 (at 0.1 M)
when
compared to vehicle. Compound 1 was able to inhibit IL-27 induced CXCL10
secretion by
108% 11 (at 10 M), 98% 10 (at 104) and 73% 8.5 (at 0.1 M) when compared to
47
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
vehicle control. Compound 1 was able to inhibit IL-27 induced CXCL9 secretion
by 100%
-0 (at 101.tM), 95% 3.7 (at 11.tM) and 75% 3.5 (at 0.1 M) when compared to
vehicle
control.
Assay 16: IL-5 mediated eosinophil survival assay
The potency of the test compound for IL-5 mediated eosinophil survival was
measured in human eosinophils isolated from human whole blood (AllCells).
Because IL-5
signals through JAK, this assay provides a measure of JAK cellular potency.
Human eosinophils were isolated from fresh human whole blood (AllCells) of
healthy
donors. Blood was mixed with 4.5% Dextran (Sigma-Aldrich) in a 0.9% sodium
chloride
solution (Sigma-Aldrich). Red blood cells were left to sediment for 35
minutes. The
leukocyte rich upper layer was removed and layered over Ficoll-Paque (GE
Healthcare) and
centrifuged at 600g for 30 minutes. The plasma and mononuclear cell layers
were removed
before the granulocyte layer was lysed with water to remove any contaminating
red blood
cells. Eosinophils were further purified using a human eosinophil isolation
kit (Miltenyi
Biotec). A fraction of the purified eosinophils were incubated with anti-CD16
FITC
(Miltenyi Biotec) for 10 minutes at 4 C in the dark. Purity was analyzed using
a LSRTI flow
cytometer (BD Biosciences).
Cells were cultured in a 37 C, 5% CO2 humidified incubator in RPM! 1640 (Life
Technologies) supplemented with 10% Heat Inactivated Fetal Bovine Serum (FBS,
Life
Technologies), 2mM Glutamax (Life Technologies), 25mM HEPES (Life
Technologies) and
IX Pen/Strep (Life Technologies). Cells were seeded at 10,000 cells/well in
media (50 Al
The plate was centrifuged at 300g for 5 minutes and supernatants removed.
Compounds
were serially diluted in DMSO and then diluted another 500-fold to a 2x final
assay
concentration in media. Test compounds (501AL/well) were added to cells, and
incubated at
37 C, 5 % CO2 for 1 hour, followed by the addition of IL-5 (R&D Systems;
final
concentrations 1 ng/mL and 10 pg/ml) in pre-warmed assay media (50 tiL) for 72
hours.
After cytokine stimulation, cells were centrifuged at 300 g for 5 min and
washed
twice with cold DPBS (Life Technologies). To access viability and apoptosis,
cells were
incubated with Propidium Iodide (Thermo Fisher Scientific) and APC Annexin V
(BD
Biosciences) and analyzed using a LSRII flow cytometer (BD Biosciences). IC5o
values
were determined from analysis of the viability curves of percent cell
viability vs compound
48
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
concentration. Data are expressed as pICso (negative decadic logarithm IC50)
values.
Compound 1 exhibited a pIC5avalue of 7.9 0.5 in the presence of 10 pg/ml IL-5
and a pICso
value of 6.5 0.2 in the presence of 1 ng/ml IL-5.
Assay 17: Pharmacodynamic Assay: Inhibition of IFNy-induced pSTAT1 in
Rabbit Eyes
The ability of a single intravitreal administration of test compound to
inhibit
interferon-gamma (1FNy) induced phosphorylation of STAT1 protein (pSTAT1) was
measured in rabbit retinaichoroid tissue.
A suspension formulation was prepared by combining compound 1 of Example 1,
with 0.5 % hydroxypropyl methylcellulose (HPMC E5), 0.02 % Tween 80, and 9
mg/mL
sodium chloride in purified water to attain a target concentration of 20
mg/mL.
Male, New Zealand White rabbits (Liveon Biolabs, India) were used for the
studies.
Animals were acclimated after arrival at the research facilities (Jubilant
Biosys Ltd., India).
Each rabbit was given a total of two intravitreal (IVT) injections with a
total dose volume of
504 per eye. The first IVT injection (451.11, per eye) delivered 0.9 mg of
test compound or
vehicle. One week later, a second IVT injection (5 tit per eye) delivered
IFN), (1 1.tgleye;
stock solution 1 mg/mL; Kingfisher Biotech) or vehicle for the induction of IP-
10. On the
day of the injections, rabbits were anesthetized with an intramuscular
injection of ketamine
(35 mg/kg) and xylazine (5 mg/kg). Once deeply anesthetized, each eye was
rinsed with
sterile saline and IVT injections were performed using a 0.5 mL insulin
syringe
(50 units.5 mL) with a 31-gauge needle at the supra-nasal side of the both
eyes by marking
the position with a Braunstein fixed caliper (2 3/4") 3.5 mm from the rectus
muscle and 4
mm from the limbus.
Tissues were collected 2 hours after the second IVT injection with IFNI,.
Retina/choroid tissues (R/C) were collected and homogenized, and pSTAT1 levels
were
measured by quantitative Western Blot on the ProteinSimple WES instrument. The
percent
inhibition of IFNT-induced pSTAT1 was calculated in comparison to the
vehicle/vehicle and
vehicle/IFN), groups.
With a 1 week pre-treatment prior to the IFN), challenge, the suspension
formulation
of compound 1 of Example 1 inhibited 1FNy-induced pSTAT1 by 85%.
49
CA 03059785 2019-10-10
WO 2018/204233 PCT/US2018/030140
While the present invention has been described with reference to specific
aspects or
embodiments thereof, it will be understood by those of ordinary skilled in the
art that various
changes can be made or equivalents can be substituted without departing from
the true spirit
and scope of the invention. Additionally, to the extent permitted by
applicable patent statutes
and regulations, all publications, patents and patent applications cited
herein are hereby
incorporated by reference in their entirety to the same extent as if each
document had been
individually incorporated by reference herein.
50
